JP5213229B2 - キナーゼ調節因子および使用方法 - Google Patents
キナーゼ調節因子および使用方法 Download PDFInfo
- Publication number
- JP5213229B2 JP5213229B2 JP2007509678A JP2007509678A JP5213229B2 JP 5213229 B2 JP5213229 B2 JP 5213229B2 JP 2007509678 A JP2007509678 A JP 2007509678A JP 2007509678 A JP2007509678 A JP 2007509678A JP 5213229 B2 JP5213229 B2 JP 5213229B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrazolo
- piperazin
- pyrimidin
- bromo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 76
- 108091000080 Phosphotransferase Proteins 0.000 title claims description 42
- 102000020233 phosphotransferase Human genes 0.000 title claims description 42
- -1 2,5-dioxopyrrolidin-1-yl Chemical group 0.000 claims description 286
- 150000001875 compounds Chemical class 0.000 claims description 208
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 184
- 239000000203 mixture Substances 0.000 claims description 145
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 88
- 239000011541 reaction mixture Substances 0.000 claims description 85
- 230000000694 effects Effects 0.000 claims description 61
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 45
- 125000004122 cyclic group Chemical group 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000003107 substituted aryl group Chemical group 0.000 claims description 21
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 102000001253 Protein Kinase Human genes 0.000 claims description 15
- 108060006633 protein kinase Proteins 0.000 claims description 15
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 13
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- VXOGMIMOLDTFBZ-UHFFFAOYSA-N 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 VXOGMIMOLDTFBZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- YDCPJETYANMVFW-UHFFFAOYSA-N 2-[3-[4-[1-tert-butyl-3-(trifluoromethyl)pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-5-chloro-2-methylphenoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NN(C=3N=CN=2)C(C)(C)C)C(F)(F)F)=C1C YDCPJETYANMVFW-UHFFFAOYSA-N 0.000 claims description 3
- FRSGTYFDKGJXNW-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)-5-(3,3,3-trifluoropropoxy)aniline Chemical compound C1=C(OCCC(F)(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 FRSGTYFDKGJXNW-UHFFFAOYSA-N 0.000 claims description 3
- OJSJVZOGAFBPJE-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C=NNC=3N=CN=2)CC1 OJSJVZOGAFBPJE-UHFFFAOYSA-N 0.000 claims description 3
- IYFFGVGWWQJVFY-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C IYFFGVGWWQJVFY-UHFFFAOYSA-N 0.000 claims description 3
- KFJYAVVIRNQQKI-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CCC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C KFJYAVVIRNQQKI-UHFFFAOYSA-N 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- CFDGOSRQZCDYHK-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylic acid Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1C(O)=O)CCN1C1=CC=CC(Cl)=C1 CFDGOSRQZCDYHK-UHFFFAOYSA-N 0.000 claims description 2
- OFDSSLFGGWSMMJ-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]butan-1-one Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)CCC)=CC=1NCCN1CCCC1 OFDSSLFGGWSMMJ-UHFFFAOYSA-N 0.000 claims description 2
- DCNODYHFBSBLGN-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]pentan-1-one Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)CCCC)=CC=1NCCN1CCCC1 DCNODYHFBSBLGN-UHFFFAOYSA-N 0.000 claims description 2
- HPIIDXXXXRXUCH-UHFFFAOYSA-N 1-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]isoquinoline Chemical compound C1=CC=C2C(N3CCN(CC3)C=3N=CN=C4NN=C(C=34)CC)=NC=CC2=C1 HPIIDXXXXRXUCH-UHFFFAOYSA-N 0.000 claims description 2
- TZFORYKWKFKQQB-UHFFFAOYSA-N 1-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methoxyphenyl]-n,n-dimethylmethanamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(CN(C)C)=C1OC TZFORYKWKFKQQB-UHFFFAOYSA-N 0.000 claims description 2
- HRQVYTNMNDWJAQ-UHFFFAOYSA-N 2-chloro-4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenol Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=C(O)C=C1C HRQVYTNMNDWJAQ-UHFFFAOYSA-N 0.000 claims description 2
- AJWFNKDUKOFVSO-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethynyl)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(C#CC=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 AJWFNKDUKOFVSO-UHFFFAOYSA-N 0.000 claims description 2
- HGCQHRUBKWVKHA-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC1=NOC(C=2C=C(C(C)=C(NCCN3CCCC3)C=2)N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=N1 HGCQHRUBKWVKHA-UHFFFAOYSA-N 0.000 claims description 2
- YWUIVMBLSSVYOU-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-methylsulfonyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(S(C)(=O)=O)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 YWUIVMBLSSVYOU-UHFFFAOYSA-N 0.000 claims description 2
- DRFKNPFAXPCTQG-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2,2-dimethylpropoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC(C)(C)C)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 DRFKNPFAXPCTQG-UHFFFAOYSA-N 0.000 claims description 2
- BZWINHLDUBAFJC-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(CCC(C)(C)C)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 BZWINHLDUBAFJC-UHFFFAOYSA-N 0.000 claims description 2
- MZMMBFATXSYGDE-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(cyclobutylmethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC2CCC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 MZMMBFATXSYGDE-UHFFFAOYSA-N 0.000 claims description 2
- IYGKFXLAHMDZHD-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(cyclopentylmethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC2CCCC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 IYGKFXLAHMDZHD-UHFFFAOYSA-N 0.000 claims description 2
- YYRHQZUDEOMFMB-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,2-difluorocyclopropyl)methoxy]-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC2C(C2)(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 YYRHQZUDEOMFMB-UHFFFAOYSA-N 0.000 claims description 2
- LYDIYXALBYBXDU-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethylsulfonyl-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(S(=O)(=O)CC)=CC=1NCCN1CCCC1 LYDIYXALBYBXDU-UHFFFAOYSA-N 0.000 claims description 2
- LWZBMXSUTVCFDI-UHFFFAOYSA-N 3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(OCC(C)C)=CC=1NCCN1CCCC1 LWZBMXSUTVCFDI-UHFFFAOYSA-N 0.000 claims description 2
- FVTGZBCGLSOVNH-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C#CCO)=NNC=3N=CN=2)CC1 FVTGZBCGLSOVNH-UHFFFAOYSA-N 0.000 claims description 2
- ITZRTIPTIGXEDC-UHFFFAOYSA-N 3-benzyl-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(CC=4C=CC=CC=4)=NNC=3N=CN=2)CC1 ITZRTIPTIGXEDC-UHFFFAOYSA-N 0.000 claims description 2
- ZXVQZHJGOFVOMR-UHFFFAOYSA-N 3-bromo-4-[4-(2,5-difluorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound FC1=CC=C(F)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 ZXVQZHJGOFVOMR-UHFFFAOYSA-N 0.000 claims description 2
- QTGCAQPANBHFRY-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1CCCN1CCCC1 QTGCAQPANBHFRY-UHFFFAOYSA-N 0.000 claims description 2
- LVCUTRIUEIMSSN-UHFFFAOYSA-N 3-bromo-5-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-n-phenylbenzamide Chemical compound C1=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C(Br)C=C1C(=O)NC1=CC=CC=C1 LVCUTRIUEIMSSN-UHFFFAOYSA-N 0.000 claims description 2
- ZUGWVLCGKRAMCK-UHFFFAOYSA-N 3-ethyl-4-(4-phenylpiperazin-1-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC=C1 ZUGWVLCGKRAMCK-UHFFFAOYSA-N 0.000 claims description 2
- ABCLBFFJWCINQC-UHFFFAOYSA-N 3-ethyl-4-[4-(3-methoxy-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC(OC)=C1C ABCLBFFJWCINQC-UHFFFAOYSA-N 0.000 claims description 2
- DSUZVNZHENWVEH-UHFFFAOYSA-N 3-ethyl-4-[4-(3-methoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC(OC)=C1 DSUZVNZHENWVEH-UHFFFAOYSA-N 0.000 claims description 2
- NQGUYIIGRJFWGT-UHFFFAOYSA-N 3-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC=C1C NQGUYIIGRJFWGT-UHFFFAOYSA-N 0.000 claims description 2
- SXKQDCIDBSRHGY-UHFFFAOYSA-N 4-(3-chlorophenyl)-1-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-n-methylpiperazine-2-carboxamide Chemical compound C=12C(CC)=NNC2=NC=NC=1N(C(C1)C(=O)NC)CCN1C1=CC=CC(Cl)=C1 SXKQDCIDBSRHGY-UHFFFAOYSA-N 0.000 claims description 2
- RPGYWHYWENYQGY-UHFFFAOYSA-N 4-(4-phenylpiperazin-1-yl)-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C=2C=3C=NNC=3N=CN=2)CCN1C1=CC=CC=C1 RPGYWHYWENYQGY-UHFFFAOYSA-N 0.000 claims description 2
- DBHLLUYXGVGCBT-UHFFFAOYSA-N 4-[2-[2-chloro-4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenoxy]ethyl]morpholine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=C1Cl)=CC=C1OCCN1CCOCC1 DBHLLUYXGVGCBT-UHFFFAOYSA-N 0.000 claims description 2
- UQLMPDRFVRHEEC-UHFFFAOYSA-N 4-[4-(2,5-difluorophenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(F)=CC=C1F UQLMPDRFVRHEEC-UHFFFAOYSA-N 0.000 claims description 2
- HWUXRXXIRBYCNK-UHFFFAOYSA-N 4-[4-(2-methylphenyl)piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=CC=C1N1CCN(C=2C=3C=NNC=3N=CN=2)CC1 HWUXRXXIRBYCNK-UHFFFAOYSA-N 0.000 claims description 2
- OIQHXDDUNABRJN-UHFFFAOYSA-N 4-[4-(3,6-dimethylpyrazin-2-yl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=NC(C)=CN=C1C OIQHXDDUNABRJN-UHFFFAOYSA-N 0.000 claims description 2
- ZTTZSXXHUDNUPX-UHFFFAOYSA-N 4-[4-(3-bromo-2-chloro-5-fluorophenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(F)=CC(Br)=C1Cl ZTTZSXXHUDNUPX-UHFFFAOYSA-N 0.000 claims description 2
- XATAOMSNDMSGSO-UHFFFAOYSA-N 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC(Cl)=C1 XATAOMSNDMSGSO-UHFFFAOYSA-N 0.000 claims description 2
- YXAQKJOQSNRGHK-UHFFFAOYSA-N 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC(Cl)=C1 YXAQKJOQSNRGHK-UHFFFAOYSA-N 0.000 claims description 2
- FFLJZUPHFGTAMD-UHFFFAOYSA-N 4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=NC(C)=CC(C)=N1 FFLJZUPHFGTAMD-UHFFFAOYSA-N 0.000 claims description 2
- TZRRXZFUOZMLHU-UHFFFAOYSA-N 4-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1OC TZRRXZFUOZMLHU-UHFFFAOYSA-N 0.000 claims description 2
- JDRLXIDHAYBNRM-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methoxyethoxymethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(COCCOC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C JDRLXIDHAYBNRM-UHFFFAOYSA-N 0.000 claims description 2
- WSHLJCGMVSJNMB-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methylpropyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC(C)C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C WSHLJCGMVSJNMB-UHFFFAOYSA-N 0.000 claims description 2
- PEXFLFCCUBQENE-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylpiperazin-1-yl)-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCN1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 PEXFLFCCUBQENE-UHFFFAOYSA-N 0.000 claims description 2
- BXXGWPDHOXTRRE-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)CC1 BXXGWPDHOXTRRE-UHFFFAOYSA-N 0.000 claims description 2
- HGNLAXAYDKLPAN-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C HGNLAXAYDKLPAN-UHFFFAOYSA-N 0.000 claims description 2
- QMRYFQJVJSUZLY-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-6-phenyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C)=NNC2=NC(C=2C=CC=CC=2)=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C QMRYFQJVJSUZLY-UHFFFAOYSA-N 0.000 claims description 2
- DBBPQRUDHSGXGI-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-phenyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC=CC=4)=NNC=3N=CN=2)CC1 DBBPQRUDHSGXGI-UHFFFAOYSA-N 0.000 claims description 2
- GVPKPIYHQSAUFM-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propan-2-yl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C(C)C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C GVPKPIYHQSAUFM-UHFFFAOYSA-N 0.000 claims description 2
- CUTHWLLCENKSGW-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-ethyl-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C=NNC2=NC(CC)=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C CUTHWLLCENKSGW-UHFFFAOYSA-N 0.000 claims description 2
- PRVDHIXOOBBJFD-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-methyl-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C=NNC2=NC(C)=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C PRVDHIXOOBBJFD-UHFFFAOYSA-N 0.000 claims description 2
- PZPHGLIZCQICOD-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-propan-2-yl-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C=NNC2=NC(C(C)C)=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C PZPHGLIZCQICOD-UHFFFAOYSA-N 0.000 claims description 2
- VUZSRKURYLGNGT-UHFFFAOYSA-N 4-[4-(5-chloro-3-methoxy-2-methylphenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(OC)=C1C VUZSRKURYLGNGT-UHFFFAOYSA-N 0.000 claims description 2
- MYAYFLXJENQGNP-UHFFFAOYSA-N 4-[4-(5-chloro-4-methoxy-2-methylphenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=C(OC)C=C1C MYAYFLXJENQGNP-UHFFFAOYSA-N 0.000 claims description 2
- MOWCFUDCJQIYNA-UHFFFAOYSA-N 4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC2)C=2C=3C=NNC=3N=CN=2)=C1 MOWCFUDCJQIYNA-UHFFFAOYSA-N 0.000 claims description 2
- BJVXKHFOWCDPLN-UHFFFAOYSA-N 4-[4-[3-chloro-4-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=C1Cl)=CC=C1OCCN1CCCCC1 BJVXKHFOWCDPLN-UHFFFAOYSA-N 0.000 claims description 2
- PBHIIIVVBPIJSN-UHFFFAOYSA-N 4-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2H-pyrazolo[3,4-d]pyrimidin-3-yl]phenol Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(O)=CC=4)=NNC=3N=CN=2)CC1 PBHIIIVVBPIJSN-UHFFFAOYSA-N 0.000 claims description 2
- DARRPJUVNRFGQX-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(1-methylpiperidin-4-yl)ethoxy]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCC1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C DARRPJUVNRFGQX-UHFFFAOYSA-N 0.000 claims description 2
- UIIOSEYTZDZNAG-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCN1CCCC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C UIIOSEYTZDZNAG-UHFFFAOYSA-N 0.000 claims description 2
- FRYZXWBIDBKNTC-UHFFFAOYSA-N 4-[5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N1CC2CC1CN2C1=CC=CC(Cl)=C1 FRYZXWBIDBKNTC-UHFFFAOYSA-N 0.000 claims description 2
- ZEGDVMSZKIZCEO-UHFFFAOYSA-N 4-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]morpholine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1N1CCOCC1 ZEGDVMSZKIZCEO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- PHHJAFUIIRWPQI-UHFFFAOYSA-N 5-bromo-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylaniline Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Br)=CC(N)=C1C PHHJAFUIIRWPQI-UHFFFAOYSA-N 0.000 claims description 2
- OGKBRMWNHGMVFX-UHFFFAOYSA-N 5-chloro-2-methyl-n-(2-pyrrolidin-1-ylethyl)-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]aniline Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1NCCN1CCCC1 OGKBRMWNHGMVFX-UHFFFAOYSA-N 0.000 claims description 2
- BKYQHYYQDPBHJM-UHFFFAOYSA-N [5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1OC)=CC(Cl)=CC=1C(=O)N1CCN(C)CC1 BKYQHYYQDPBHJM-UHFFFAOYSA-N 0.000 claims description 2
- XRLQDQSANHSNIL-UHFFFAOYSA-N [5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methoxyphenyl]methanol Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(CO)=C1OC XRLQDQSANHSNIL-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- WYIZYVTVOHRTSK-UHFFFAOYSA-N n'-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n,n,n'-trimethylethane-1,2-diamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(N(C)CCN(C)C)=C1C WYIZYVTVOHRTSK-UHFFFAOYSA-N 0.000 claims description 2
- UKRKRPLHUUSIOI-UHFFFAOYSA-N n,n-diethyl-2-[3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]ethanamine Chemical compound CCN(CC)CCOC1=CC=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C UKRKRPLHUUSIOI-UHFFFAOYSA-N 0.000 claims description 2
- QPJAQDDXUMCFFT-UHFFFAOYSA-N n-[3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-ynyl]acetamide Chemical compound C=12C(C#CCNC(=O)C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C QPJAQDDXUMCFFT-UHFFFAOYSA-N 0.000 claims description 2
- IXQLYMMGMJNIFK-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C IXQLYMMGMJNIFK-UHFFFAOYSA-N 0.000 claims description 2
- CEWFUFAYEYMGEO-UHFFFAOYSA-N n-[[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methoxyphenyl]methyl]-n',n'-dimethylethane-1,2-diamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(CNCCN(C)C)=C1OC CEWFUFAYEYMGEO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- OSZJZLURIWBTMR-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 OSZJZLURIWBTMR-UHFFFAOYSA-N 0.000 claims 3
- AGGZVELGCPADHT-UHFFFAOYSA-N N'-(2-pyrrolidin-1-ylethyl)benzohydrazide Chemical compound C(C1=CC=CC=C1)(=O)NNCCN1CCCC1 AGGZVELGCPADHT-UHFFFAOYSA-N 0.000 claims 3
- IJBZFRMMDXVGCU-SNAWJCMRSA-N (e)-3-[4-[4-[5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methyl-3-(2-pyrrolidin-1-ylethylamino)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=C(OCC(F)(CF)CF)C=C(N2CCN(CC2)C=2C=3C(\C=C\C(O)=O)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 IJBZFRMMDXVGCU-SNAWJCMRSA-N 0.000 claims 2
- VEUAGFBTUOWMGS-UHFFFAOYSA-N 1-[2-[2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylphenyl]phenoxy]ethyl]pyrrolidine-2,5-dione Chemical compound C1=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=CC=C1C1=CC=CC=C1OCCN1C(=O)CCC1=O VEUAGFBTUOWMGS-UHFFFAOYSA-N 0.000 claims 2
- IKBSEBRGSVFUHM-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-4,4,4-trifluorobutan-1-one Chemical compound C1=C(C(=O)CCC(F)(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 IKBSEBRGSVFUHM-UHFFFAOYSA-N 0.000 claims 2
- AEPBFFNXZJQDMU-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]butan-1-ol Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(O)CCC)=CC=1NCCN1CCCC1 AEPBFFNXZJQDMU-UHFFFAOYSA-N 0.000 claims 2
- JPGSIPPBCGKIIU-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-pyrrolidin-1-ylethylamino)phenyl]butan-1-one Chemical compound C=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)CCC)=CC=1NCCN1CCCC1 JPGSIPPBCGKIIU-UHFFFAOYSA-N 0.000 claims 2
- CXWRIIBHGFNKAV-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)-5-(2,2,2-trifluoroethoxy)aniline Chemical compound C1=C(OCC(F)(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 CXWRIIBHGFNKAV-UHFFFAOYSA-N 0.000 claims 2
- YJOVRFFTOQUZOT-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)-5-(2,2,2-trifluoroethoxymethyl)aniline Chemical compound C1=C(COCC(F)(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 YJOVRFFTOQUZOT-UHFFFAOYSA-N 0.000 claims 2
- ZFGPLQJDDUAPLD-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(1,1-difluorobutyl)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(F)(F)CCC)=CC=1NCCN1CCCC1 ZFGPLQJDDUAPLD-UHFFFAOYSA-N 0.000 claims 2
- XFVUESCLIPSCDS-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethoxymethyl)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(COCC)=CC=1NCCN1CCCC1 XFVUESCLIPSCDS-UHFFFAOYSA-N 0.000 claims 2
- DNEVYQASLHDDSQ-UHFFFAOYSA-N 3-[4-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-1-methyl-6-(trifluoromethyl)benzimidazol-2-yl]propan-1-ol Chemical compound C1=C(C(F)(F)F)C=C2N(C)C(CCCO)=NC2=C1N(CC1)CCN1C1=NC=NC2=C1C(Br)=NN2 DNEVYQASLHDDSQ-UHFFFAOYSA-N 0.000 claims 2
- SMNSMHSHWGBIFH-UHFFFAOYSA-N 3-[4-[4-[5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methyl-3-(2-pyrrolidin-1-ylethylamino)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol Chemical compound C1=C(OCC(F)(CF)CF)C=C(N2CCN(CC2)C=2C=3C(C#CCO)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 SMNSMHSHWGBIFH-UHFFFAOYSA-N 0.000 claims 2
- RAQLRASZPYFRHR-UHFFFAOYSA-N 3-bromo-4-[4-[2-chloro-5-[4-fluoro-2-(2-pyrrolidin-1-ylethoxy)phenyl]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=1C(F)=CC=C(C=2C=C(C(Cl)=CC=2)N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C=1OCCN1CCCC1 RAQLRASZPYFRHR-UHFFFAOYSA-N 0.000 claims 2
- NCUIHEKCQCSDGR-UHFFFAOYSA-N 3-bromo-4-[4-[5-[3-fluoro-2-(2-pyrrolidin-1-ylethoxy)phenyl]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=CC=C1C1=CC=CC(F)=C1OCCN1CCCC1 NCUIHEKCQCSDGR-UHFFFAOYSA-N 0.000 claims 2
- MFCRUXWKACGBRB-UHFFFAOYSA-N 4-[3-[2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylphenyl]phenoxy]propyl]morpholine Chemical compound C1=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=CC=C1C1=CC=CC=C1OCCCN1CCOCC1 MFCRUXWKACGBRB-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- URDNYNTUOXZTMC-UHFFFAOYSA-N [3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-cyclopropylmethanone Chemical compound C1=C(C(=O)C2CC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 URDNYNTUOXZTMC-UHFFFAOYSA-N 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- UCHDIMBSVPCEED-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-n-methylpiperazine-2-carboxamide Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1C(=O)NC)CCN1C1=CC=CC(Cl)=C1 UCHDIMBSVPCEED-UHFFFAOYSA-N 0.000 claims 1
- JEWJTXCLTYTKGJ-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]ethanone Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)C)=CC=1NCCN1CCCC1 JEWJTXCLTYTKGJ-UHFFFAOYSA-N 0.000 claims 1
- DEJZGAXRKVTAOI-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]propan-1-one Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)CC)=CC=1NCCN1CCCC1 DEJZGAXRKVTAOI-UHFFFAOYSA-N 0.000 claims 1
- NWBMPJUVBNMTAZ-UHFFFAOYSA-N 1-[3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]pentan-1-one Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=CC(C(=O)CCCC)=CC=1NCCN1CCCC1 NWBMPJUVBNMTAZ-UHFFFAOYSA-N 0.000 claims 1
- BWMAIJPCEMKYSE-UHFFFAOYSA-N 1-[4-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 BWMAIJPCEMKYSE-UHFFFAOYSA-N 0.000 claims 1
- ANPOOPNQKGKSJT-UHFFFAOYSA-N 2-[2-chloro-4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenoxy]-n,n-dimethylethanamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=C(OCCN(C)C)C=C1C ANPOOPNQKGKSJT-UHFFFAOYSA-N 0.000 claims 1
- AQSFKKRGCGBYMT-UHFFFAOYSA-N 2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C AQSFKKRGCGBYMT-UHFFFAOYSA-N 0.000 claims 1
- YTWXXVFTSISDIU-UHFFFAOYSA-N 2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 YTWXXVFTSISDIU-UHFFFAOYSA-N 0.000 claims 1
- QACFEEHLDHOROZ-UHFFFAOYSA-N 2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenoxy]-n-cyclopropylacetamide Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C(C=1)=CC=CC=1OCC(=O)NC1CC1 QACFEEHLDHOROZ-UHFFFAOYSA-N 0.000 claims 1
- SGXWCNICGLRKLH-UHFFFAOYSA-N 2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenoxy]-n-ethylacetamide Chemical compound CCNC(=O)COC1=CC=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 SGXWCNICGLRKLH-UHFFFAOYSA-N 0.000 claims 1
- UGBZDDLNHZCSGD-UHFFFAOYSA-N 2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazin-2-yl]oxy-n,n-dimethylethanamine Chemical compound CN(C)CCOC1=NC=CN=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 UGBZDDLNHZCSGD-UHFFFAOYSA-N 0.000 claims 1
- LQLOZXZBBRYWKZ-UHFFFAOYSA-N 2-[3-chloro-5-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1 LQLOZXZBBRYWKZ-UHFFFAOYSA-N 0.000 claims 1
- ZREYJYHNHLWXMG-UHFFFAOYSA-N 2-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5,6-trifluoro-n-(3-methylbutyl)pyridin-4-amine Chemical compound CC(C)CCNC1=C(F)C(F)=NC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1F ZREYJYHNHLWXMG-UHFFFAOYSA-N 0.000 claims 1
- BYPWKEYKDJFHMZ-UHFFFAOYSA-N 2-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n,n-diethylpyrimidin-4-amine Chemical compound CCN(CC)C1=CC=NC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=N1 BYPWKEYKDJFHMZ-UHFFFAOYSA-N 0.000 claims 1
- HXUGITZLWUIORI-UHFFFAOYSA-N 2-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC=C1C#N HXUGITZLWUIORI-UHFFFAOYSA-N 0.000 claims 1
- DJMBORBQCHGPTO-UHFFFAOYSA-N 2-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carbonitrile Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=NC=CC=C1C#N DJMBORBQCHGPTO-UHFFFAOYSA-N 0.000 claims 1
- NCQPMNLBSXIPKR-UHFFFAOYSA-N 2-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C NCQPMNLBSXIPKR-UHFFFAOYSA-N 0.000 claims 1
- JJPWYGOOLUCARP-UHFFFAOYSA-N 2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methoxyphenoxy]-n,n-dimethylethanamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(OCCN(C)C)=C1OC JJPWYGOOLUCARP-UHFFFAOYSA-N 0.000 claims 1
- ZQWOIHWHSIPTIE-UHFFFAOYSA-N 2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C ZQWOIHWHSIPTIE-UHFFFAOYSA-N 0.000 claims 1
- VEMYRWOPVSXONW-UHFFFAOYSA-N 2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]-n,n-dimethylethanamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(OCCN(C)C)=C1C VEMYRWOPVSXONW-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- GTVUGPOLOIQVEI-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-2-carboxylic acid Chemical compound C1CCC2CN(C(=O)O)CC21 GTVUGPOLOIQVEI-UHFFFAOYSA-N 0.000 claims 1
- IHRWZYGUYZIWKE-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C5OCOC5=CC=4)=NNC=3N=CN=2)CC1 IHRWZYGUYZIWKE-UHFFFAOYSA-N 0.000 claims 1
- RCPMWFKCKLHIEK-UHFFFAOYSA-N 3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=C4CNC4)=NNC=3N=CN=2)CC1 RCPMWFKCKLHIEK-UHFFFAOYSA-N 0.000 claims 1
- SMJDOACCIIQIIV-GOSISDBHSA-N 3-[(2r)-4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-2-(hydroxymethyl)piperazin-1-yl]-4-methyl-n-phenylbenzamide Chemical compound C1=C(N2[C@H](CN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)CO)C(C)=CC=C1C(=O)NC1=CC=CC=C1 SMJDOACCIIQIIV-GOSISDBHSA-N 0.000 claims 1
- WLEVNSDEDNVUGR-INIZCTEOSA-N 3-[(2s)-4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-n-phenylbenzamide Chemical compound C([C@@H]1C)N(C=2C=3C(Br)=NNC=3N=CN=2)CCN1C(C(=CC=1)C)=CC=1C(=O)NC1=CC=CC=C1 WLEVNSDEDNVUGR-INIZCTEOSA-N 0.000 claims 1
- ODPLRDPJKWWTHJ-UHFFFAOYSA-N 3-[2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylphenyl]phenoxy]-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=CC=C1C1=CC=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 ODPLRDPJKWWTHJ-UHFFFAOYSA-N 0.000 claims 1
- DLMKOVRFSWGSNZ-UHFFFAOYSA-N 3-[2-chloro-4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenoxy]-n,n-dimethylpropan-1-amine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=C(OCCCN(C)C)C=C1C DLMKOVRFSWGSNZ-UHFFFAOYSA-N 0.000 claims 1
- IKUFFDDVPUPTCG-UHFFFAOYSA-N 3-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenoxy]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C IKUFFDDVPUPTCG-UHFFFAOYSA-N 0.000 claims 1
- SQMYBMIVKNUFRI-UHFFFAOYSA-N 3-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C SQMYBMIVKNUFRI-UHFFFAOYSA-N 0.000 claims 1
- ASLBGEXQSXSLDI-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin-1-yl]-4-methyl-n-phenylbenzamide Chemical compound C1=C(N2C(CN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=O)C(C)=CC=C1C(=O)NC1=CC=CC=C1 ASLBGEXQSXSLDI-UHFFFAOYSA-N 0.000 claims 1
- VWBUFACHINJXSO-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCC(C)C)=CC=1NCCN1CCCC1 VWBUFACHINJXSO-UHFFFAOYSA-N 0.000 claims 1
- JUZOYDZYOULNAP-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethyl)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(CCC=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 JUZOYDZYOULNAP-UHFFFAOYSA-N 0.000 claims 1
- WDWOGDISXRDAPH-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methylbutoxy)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCCC(C)C)=CC=1NCCN1CCCC1 WDWOGDISXRDAPH-UHFFFAOYSA-N 0.000 claims 1
- XELODWMJEHJNGC-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound O1C(C)=NC(C=2C=C(C(C)=C(NCCN3CCCC3)C=2)N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=N1 XELODWMJEHJNGC-UHFFFAOYSA-N 0.000 claims 1
- BKZVKDVSFQWXCI-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(oxolan-2-ylmethoxy)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC2OCCC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 BKZVKDVSFQWXCI-UHFFFAOYSA-N 0.000 claims 1
- IHQZZYDEVZEHEN-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-phenyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(C=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 IHQZZYDEVZEHEN-UHFFFAOYSA-N 0.000 claims 1
- HEWBPXZYOYWXGF-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-propan-2-yloxy-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OC(C)C)=CC=1NCCN1CCCC1 HEWBPXZYOYWXGF-UHFFFAOYSA-N 0.000 claims 1
- CQAFUDZJKLZILE-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-propoxy-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCCC)=CC=1NCCN1CCCC1 CQAFUDZJKLZILE-UHFFFAOYSA-N 0.000 claims 1
- FQCOMPCVEBMBGQ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)-5-(1,3-thiazol-2-yl)aniline Chemical compound C1=C(C=2SC=CN=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 FQCOMPCVEBMBGQ-UHFFFAOYSA-N 0.000 claims 1
- HUSVBQWJEQARSD-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)-5-(2-trimethylsilylethyl)aniline Chemical compound C1=C(CC[Si](C)(C)C)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 HUSVBQWJEQARSD-UHFFFAOYSA-N 0.000 claims 1
- DAGQTIZIUNGONJ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)benzoic acid Chemical compound C1=C(C(O)=O)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 DAGQTIZIUNGONJ-UHFFFAOYSA-N 0.000 claims 1
- HJFUGUJMYAFXJJ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-n-phenylbenzamide Chemical compound C1=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=CC=C1C(=O)NC1=CC=CC=C1 HJFUGUJMYAFXJJ-UHFFFAOYSA-N 0.000 claims 1
- GKNWWGIEHPFKIG-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-ethylbutoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCC(CC)CC)=CC=1NCCN1CCCC1 GKNWWGIEHPFKIG-UHFFFAOYSA-N 0.000 claims 1
- HROXMNKAOQUZSJ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-fluoro-2-methylpropoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC(C)(C)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 HROXMNKAOQUZSJ-UHFFFAOYSA-N 0.000 claims 1
- FNHNYWBZBHUBPV-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-methoxyethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCCOC)=CC=1NCCN1CCCC1 FNHNYWBZBHUBPV-UHFFFAOYSA-N 0.000 claims 1
- GMJSCDCMWJNAQQ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(cyclopropylmethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC2CC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 GMJSCDCMWJNAQQ-UHFFFAOYSA-N 0.000 claims 1
- AHLOJMPYPHADTE-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(difluoromethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OC(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 AHLOJMPYPHADTE-UHFFFAOYSA-N 0.000 claims 1
- GIBOSPRQHDUWQU-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(difluoromethoxymethyl)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(COC(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 GIBOSPRQHDUWQU-UHFFFAOYSA-N 0.000 claims 1
- LDUJWILZFQEFOV-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC(F)(CF)CF)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 LDUJWILZFQEFOV-UHFFFAOYSA-N 0.000 claims 1
- QQHQZRLEXUVJBO-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[2-(dimethylamino)ethylamino]-4-methyl-n-phenylbenzamide Chemical compound C=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C(C)C(NCCN(C)C)=CC=1C(=O)NC1=CC=CC=C1 QQHQZRLEXUVJBO-UHFFFAOYSA-N 0.000 claims 1
- NFYLJFNABIOBQQ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-butoxy-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCCCC)=CC=1NCCN1CCCC1 NFYLJFNABIOBQQ-UHFFFAOYSA-N 0.000 claims 1
- IFJNCEJQABLDMF-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(Cl)=CC=1NCCN1CCCC1 IFJNCEJQABLDMF-UHFFFAOYSA-N 0.000 claims 1
- HNGORDVZNLENER-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethoxy-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCC)=CC=1NCCN1CCCC1 HNGORDVZNLENER-UHFFFAOYSA-N 0.000 claims 1
- UQPLUMXNXTZQMI-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methoxy-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OC)=CC=1NCCN1CCCC1 UQPLUMXNXTZQMI-UHFFFAOYSA-N 0.000 claims 1
- SUPTVDNUUOFKOU-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n,4-dimethylbenzamide Chemical compound CNC(=O)C1=CC=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 SUPTVDNUUOFKOU-UHFFFAOYSA-N 0.000 claims 1
- XIQYNIPNCGZIBX-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n,n,4-trimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 XIQYNIPNCGZIBX-UHFFFAOYSA-N 0.000 claims 1
- SIODQEWTENYBSI-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n-[2-(dimethylamino)ethyl]-4-methylbenzamide Chemical compound CN(C)CCNC(=O)C1=CC=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 SIODQEWTENYBSI-UHFFFAOYSA-N 0.000 claims 1
- ZYNKXHMLHGWMFA-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazine-2-carbonitrile Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=NC=CN=C1C#N ZYNKXHMLHGWMFA-UHFFFAOYSA-N 0.000 claims 1
- VGZTWRCQVSHEPS-UHFFFAOYSA-N 3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-phenylmethoxy-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C(=C(NCCN1CCCC1)C=1)C)=CC=1OCC1=CC=CC=C1 VGZTWRCQVSHEPS-UHFFFAOYSA-N 0.000 claims 1
- SVAZQZBAUSXFFJ-UHFFFAOYSA-N 3-[4-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6-chloro-5-methylpyrimidin-2-yl]oxy-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCOC1=NC(Cl)=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=N1 SVAZQZBAUSXFFJ-UHFFFAOYSA-N 0.000 claims 1
- HBAHCSKBUFIZHI-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]aniline Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(N)C=CC=4)=NNC=3N=CN=2)CC1 HBAHCSKBUFIZHI-UHFFFAOYSA-N 0.000 claims 1
- OSZPLABAQXTERJ-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(C=CC=4)C(O)=O)=NNC=3N=CN=2)CC1 OSZPLABAQXTERJ-UHFFFAOYSA-N 0.000 claims 1
- DUZXKKRUOUCQRH-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]phenol Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(O)C=CC=4)=NNC=3N=CN=2)CC1 DUZXKKRUOUCQRH-UHFFFAOYSA-N 0.000 claims 1
- MMMKUWNVQFPSJD-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]propan-1-ol Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(CCCO)=NNC=3N=CN=2)CC1 MMMKUWNVQFPSJD-UHFFFAOYSA-N 0.000 claims 1
- UGTLNWHSTJEXDT-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]propanoic acid Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(CCC(O)=O)=NNC=3N=CN=2)CC1 UGTLNWHSTJEXDT-UHFFFAOYSA-N 0.000 claims 1
- FZGQSPDGZYNZTQ-UHFFFAOYSA-N 3-[4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(C#CCO)=NNC=3N=CN=2)C(C)=C1CCCN1CCCC1 FZGQSPDGZYNZTQ-UHFFFAOYSA-N 0.000 claims 1
- HJONXTKKZWWBEI-UHFFFAOYSA-N 3-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C HJONXTKKZWWBEI-UHFFFAOYSA-N 0.000 claims 1
- WTMZIIWPBNLGSU-UHFFFAOYSA-N 3-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenyl]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C WTMZIIWPBNLGSU-UHFFFAOYSA-N 0.000 claims 1
- RZCJHYLETSBGLY-UHFFFAOYSA-N 3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C RZCJHYLETSBGLY-UHFFFAOYSA-N 0.000 claims 1
- JNHVUMXNINQBHC-UHFFFAOYSA-N 3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C JNHVUMXNINQBHC-UHFFFAOYSA-N 0.000 claims 1
- BPORTURMMAXOII-UHFFFAOYSA-N 3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n,n-dimethylprop-2-yn-1-amine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(C#CCN(C)C)=C1C BPORTURMMAXOII-UHFFFAOYSA-N 0.000 claims 1
- KVKOQBRWNARWNE-UHFFFAOYSA-N 3-[6-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-methylpyrimidin-4-yl]oxy-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCOC1=NC(Cl)=NC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C KVKOQBRWNARWNE-UHFFFAOYSA-N 0.000 claims 1
- CMNVIOXBVGGMHC-UHFFFAOYSA-N 3-bromo-4-(4-phenylpiperazin-1-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC=C1 CMNVIOXBVGGMHC-UHFFFAOYSA-N 0.000 claims 1
- BNTQQSCEOKZDMO-UHFFFAOYSA-N 3-bromo-4-(4-pyrazin-2-ylpiperazin-1-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=CN=CC=N1 BNTQQSCEOKZDMO-UHFFFAOYSA-N 0.000 claims 1
- QAZBUEIOUQSTLE-UHFFFAOYSA-N 3-bromo-4-(4-pyridin-2-ylpiperazin-1-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=CC=N1 QAZBUEIOUQSTLE-UHFFFAOYSA-N 0.000 claims 1
- ZNZOVFHYHATGSO-UHFFFAOYSA-N 3-bromo-4-(4-pyrimidin-2-ylpiperazin-1-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=NC=CC=N1 ZNZOVFHYHATGSO-UHFFFAOYSA-N 0.000 claims 1
- KHQIGQVSEDRIKJ-LLVKDONJSA-N 3-bromo-4-[(3r)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C([C@H]1C)N(C=2C=3C(Br)=NNC=3N=CN=2)CCN1C1=CC(Cl)=CC=C1C KHQIGQVSEDRIKJ-LLVKDONJSA-N 0.000 claims 1
- KHQIGQVSEDRIKJ-NSHDSACASA-N 3-bromo-4-[(3s)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C([C@@H]1C)N(C=2C=3C(Br)=NNC=3N=CN=2)CCN1C1=CC(Cl)=CC=C1C KHQIGQVSEDRIKJ-NSHDSACASA-N 0.000 claims 1
- HXDBVSLKASWNMX-UHFFFAOYSA-N 3-bromo-4-[3-methyl-4-(3-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1CN(C=2C=3C(Br)=NNC=3N=CN=2)CCN1C1=CC=CC(C)=C1 HXDBVSLKASWNMX-UHFFFAOYSA-N 0.000 claims 1
- HVADNQGYIAOGEP-UHFFFAOYSA-N 3-bromo-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1Cl HVADNQGYIAOGEP-UHFFFAOYSA-N 0.000 claims 1
- RLQHIEAYRBMRRQ-UHFFFAOYSA-N 3-bromo-4-[4-(2,4-dichlorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC(Cl)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 RLQHIEAYRBMRRQ-UHFFFAOYSA-N 0.000 claims 1
- OTFFWCPPHHIFJB-UHFFFAOYSA-N 3-bromo-4-[4-(2,4-dimethoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=CC(OC)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 OTFFWCPPHHIFJB-UHFFFAOYSA-N 0.000 claims 1
- ZBVYWTDRJLQJFB-UHFFFAOYSA-N 3-bromo-4-[4-(2,4-dimethylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC(C)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 ZBVYWTDRJLQJFB-UHFFFAOYSA-N 0.000 claims 1
- GWRUURCRUCYCEF-UHFFFAOYSA-N 3-bromo-4-[4-(2,5-dichlorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC=C(Cl)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 GWRUURCRUCYCEF-UHFFFAOYSA-N 0.000 claims 1
- QKVBHDNWWHXBKQ-UHFFFAOYSA-N 3-bromo-4-[4-(2,6-dimethylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=CC(C)=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 QKVBHDNWWHXBKQ-UHFFFAOYSA-N 0.000 claims 1
- DWTODKDOZLKTNN-UHFFFAOYSA-N 3-bromo-4-[4-(2-ethylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CCC1=CC=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 DWTODKDOZLKTNN-UHFFFAOYSA-N 0.000 claims 1
- CQXAPCMYRSTDGK-UHFFFAOYSA-N 3-bromo-4-[4-(2-methoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=CC=CC=C1N1CCN(C=2C3=C(Br)NN=C3N=CN=2)CC1 CQXAPCMYRSTDGK-UHFFFAOYSA-N 0.000 claims 1
- XFIJPNZKILCLOW-UHFFFAOYSA-N 3-bromo-4-[4-(2-nitrophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 XFIJPNZKILCLOW-UHFFFAOYSA-N 0.000 claims 1
- PZENQFNUARUTTQ-UHFFFAOYSA-N 3-bromo-4-[4-(3,4-dichlorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 PZENQFNUARUTTQ-UHFFFAOYSA-N 0.000 claims 1
- XOTIGRBKZQTNHN-UHFFFAOYSA-N 3-bromo-4-[4-(3,4-difluorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(F)C(F)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 XOTIGRBKZQTNHN-UHFFFAOYSA-N 0.000 claims 1
- IGLANVDJAXSNRA-UHFFFAOYSA-N 3-bromo-4-[4-(3,4-dimethylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(C)C(C)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 IGLANVDJAXSNRA-UHFFFAOYSA-N 0.000 claims 1
- VUOHNLSILKQOGZ-UHFFFAOYSA-N 3-bromo-4-[4-(3,5-dichlorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 VUOHNLSILKQOGZ-UHFFFAOYSA-N 0.000 claims 1
- NMMXPVBLDKUDAW-UHFFFAOYSA-N 3-bromo-4-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 NMMXPVBLDKUDAW-UHFFFAOYSA-N 0.000 claims 1
- YKAMPLLTQDGYHQ-UHFFFAOYSA-N 3-bromo-4-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C(F)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 YKAMPLLTQDGYHQ-UHFFFAOYSA-N 0.000 claims 1
- NJUZQTKLBLLKNB-UHFFFAOYSA-N 3-bromo-4-[4-(3-chlorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 NJUZQTKLBLLKNB-UHFFFAOYSA-N 0.000 claims 1
- XKKYDENFHXAFLA-UHFFFAOYSA-N 3-bromo-4-[4-(3-methoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=CC=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 XKKYDENFHXAFLA-UHFFFAOYSA-N 0.000 claims 1
- AJETWHHIDCIIFF-UHFFFAOYSA-N 3-bromo-4-[4-(3-methoxypyrazin-2-yl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=NC=CN=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 AJETWHHIDCIIFF-UHFFFAOYSA-N 0.000 claims 1
- GJFGRMNSKDWZCR-UHFFFAOYSA-N 3-bromo-4-[4-(4-bromophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=C(Br)C=C1 GJFGRMNSKDWZCR-UHFFFAOYSA-N 0.000 claims 1
- OARRIXBHAFQNGW-UHFFFAOYSA-N 3-bromo-4-[4-(4-ethoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(OCC)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 OARRIXBHAFQNGW-UHFFFAOYSA-N 0.000 claims 1
- CONWTRAMVJTTNB-UHFFFAOYSA-N 3-bromo-4-[4-(4-fluorophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(F)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 CONWTRAMVJTTNB-UHFFFAOYSA-N 0.000 claims 1
- CMSOTWVWWGTOCD-UHFFFAOYSA-N 3-bromo-4-[4-(4-nitrophenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 CMSOTWVWWGTOCD-UHFFFAOYSA-N 0.000 claims 1
- MJTYOEDASCWGNL-UHFFFAOYSA-N 3-bromo-4-[4-(4-phenylmethoxyphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C(C=C1)=CC=C1OCC1=CC=CC=C1 MJTYOEDASCWGNL-UHFFFAOYSA-N 0.000 claims 1
- SHZNSNDAIKQSQV-UHFFFAOYSA-N 3-bromo-4-[4-[2-(trifluoromethyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound FC(F)(F)C1=CC=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 SHZNSNDAIKQSQV-UHFFFAOYSA-N 0.000 claims 1
- DCAOYMUUNJOKSB-UHFFFAOYSA-N 3-bromo-4-[4-[2-methyl-5-(2-methylpropoxy)-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCC(C)C)=CC=1CCCN1CCCC1 DCAOYMUUNJOKSB-UHFFFAOYSA-N 0.000 claims 1
- GZQAOQAIVFTXBT-UHFFFAOYSA-N 3-bromo-4-[4-[2-methyl-5-phenyl-3-(3-pyridin-1-ium-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(C=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1CCC[N+]1=CC=CC=C1 GZQAOQAIVFTXBT-UHFFFAOYSA-N 0.000 claims 1
- JZMNQCWLQJMJJQ-UHFFFAOYSA-N 3-bromo-4-[4-[3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C(C=1)=CC=CC=1OCCN1CCCCC1 JZMNQCWLQJMJJQ-UHFFFAOYSA-N 0.000 claims 1
- GHUFQOINANIXTK-UHFFFAOYSA-N 3-bromo-4-[4-[3-(2-piperidin-1-ylethoxy)pyrazin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=NC=CN=C1OCCN1CCCCC1 GHUFQOINANIXTK-UHFFFAOYSA-N 0.000 claims 1
- JLMAYHBMKURLET-UHFFFAOYSA-N 3-bromo-4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 JLMAYHBMKURLET-UHFFFAOYSA-N 0.000 claims 1
- ULNFDXASZYQCIC-UHFFFAOYSA-N 3-bromo-4-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound FC(F)(F)C1=CC=CN=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 ULNFDXASZYQCIC-UHFFFAOYSA-N 0.000 claims 1
- DGKZAYJXHQGDRL-UHFFFAOYSA-N 3-bromo-4-[4-[3-[(3-methylphenyl)methoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=CC(COC=2C=C(C=CC=2)N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 DGKZAYJXHQGDRL-UHFFFAOYSA-N 0.000 claims 1
- WSFCJBDCDVWWPR-UHFFFAOYSA-N 3-bromo-4-[4-[3-bromo-5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=C(Br)C=C(OCC(F)(CF)CF)C=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 WSFCJBDCDVWWPR-UHFFFAOYSA-N 0.000 claims 1
- VBHFWMSSEZZUDB-UHFFFAOYSA-N 3-bromo-4-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC(C(F)(F)F)=CN=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 VBHFWMSSEZZUDB-UHFFFAOYSA-N 0.000 claims 1
- WTRRDUPRZHYBMD-UHFFFAOYSA-N 3-bromo-4-[4-[4-(furan-2-yl)pyrimidin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C(N=1)=NC=CC=1C1=CC=CO1 WTRRDUPRZHYBMD-UHFFFAOYSA-N 0.000 claims 1
- RQVHKXWGBFPZNU-UHFFFAOYSA-N 3-bromo-4-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 RQVHKXWGBFPZNU-UHFFFAOYSA-N 0.000 claims 1
- NVNDCSVWPGQNIH-UHFFFAOYSA-N 3-bromo-4-[4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound FC(F)(F)C1=CC=NC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 NVNDCSVWPGQNIH-UHFFFAOYSA-N 0.000 claims 1
- GTOPXVPNCNNXLW-UHFFFAOYSA-N 3-bromo-4-[4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound FC(F)(F)C1=CC=NC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=N1 GTOPXVPNCNNXLW-UHFFFAOYSA-N 0.000 claims 1
- UQXOTKGBLBLLEJ-UHFFFAOYSA-N 3-bromo-4-[4-[4-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C=C1OCCN1CCCC1 UQXOTKGBLBLLEJ-UHFFFAOYSA-N 0.000 claims 1
- FDYRBFONKISFFU-UHFFFAOYSA-N 3-bromo-4-[4-[4-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C=C1CCCN1CCCC1 FDYRBFONKISFFU-UHFFFAOYSA-N 0.000 claims 1
- JBRKDJZHLSVLLA-UHFFFAOYSA-N 3-bromo-4-[4-[5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(OCC(F)(CF)CF)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1CCCN1CCCC1 JBRKDJZHLSVLLA-UHFFFAOYSA-N 0.000 claims 1
- UOALCMPNVGOVDK-UHFFFAOYSA-N 3-bromo-4-[4-[5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(OCC(F)(CF)CF)C=C1N1CCN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 UOALCMPNVGOVDK-UHFFFAOYSA-N 0.000 claims 1
- JHITWGOEXOEWQD-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1OCCN1CCCCC1 JHITWGOEXOEWQD-UHFFFAOYSA-N 0.000 claims 1
- XPZWAIMVIPQEMM-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1OCCN1CCCC1 XPZWAIMVIPQEMM-UHFFFAOYSA-N 0.000 claims 1
- BKEGNPFOPJZHEG-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1CCCN1CCCCC1 BKEGNPFOPJZHEG-UHFFFAOYSA-N 0.000 claims 1
- MGZUHAQRVCAGIQ-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCC1COC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C MGZUHAQRVCAGIQ-UHFFFAOYSA-N 0.000 claims 1
- BWKXOAKSFYCWNB-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[2-(1-methylpiperidin-4-yl)ethoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCC1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C BWKXOAKSFYCWNB-UHFFFAOYSA-N 0.000 claims 1
- BXUHUHGWLOFGKA-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C BXUHUHGWLOFGKA-UHFFFAOYSA-N 0.000 claims 1
- RZIMJZUGEXCLDX-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-3-[2-(4-ethylpiperazin-1-yl)ethoxy]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C RZIMJZUGEXCLDX-UHFFFAOYSA-N 0.000 claims 1
- UZQJMNDBBURGNW-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-3-[3-(4-ethylpiperazin-1-yl)propoxy]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C UZQJMNDBBURGNW-UHFFFAOYSA-N 0.000 claims 1
- JRCOATCNMDGXOI-UHFFFAOYSA-N 3-bromo-4-[4-[5-fluoro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1CCCN1CCCC1 JRCOATCNMDGXOI-UHFFFAOYSA-N 0.000 claims 1
- MBYGSMUFVUTPIB-UHFFFAOYSA-N 3-bromo-5-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C(C=1)=CC(Br)=CC=1NCCN1CCCC1 MBYGSMUFVUTPIB-UHFFFAOYSA-N 0.000 claims 1
- RQVCBFVLFOELEY-UHFFFAOYSA-N 3-bromo-5-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-n-phenylbenzamide Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C(=C(Br)C=1)C)=CC=1C(=O)NC1=CC=CC=C1 RQVCBFVLFOELEY-UHFFFAOYSA-N 0.000 claims 1
- HYDOMGRCFKLOMU-UHFFFAOYSA-N 3-ethyl-4-[4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(C(F)(F)F)=CC=N1 HYDOMGRCFKLOMU-UHFFFAOYSA-N 0.000 claims 1
- CVMGWJJUNNHKEO-UHFFFAOYSA-N 3-methyl-4-[4-[4-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C)=NNC2=NC=NC=1N(CC1)CCN1C(C=1)=CC=C(C)C=1OCCN1CCCC1 CVMGWJJUNNHKEO-UHFFFAOYSA-N 0.000 claims 1
- YIZQSXLPFSEWNO-UHFFFAOYSA-N 4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)piperazin-2-one Chemical compound CC1=CC=C(Cl)C=C1N1C(=O)CN(C=2C=3C(Br)=NNC=3N=CN=2)CC1 YIZQSXLPFSEWNO-UHFFFAOYSA-N 0.000 claims 1
- VGARQGDBXVXNBU-UHFFFAOYSA-N 4-[2-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenoxy]ethyl]morpholine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1OCCN1CCOCC1 VGARQGDBXVXNBU-UHFFFAOYSA-N 0.000 claims 1
- DDSNBPYIVBWXGB-UHFFFAOYSA-N 4-[2-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]ethyl]morpholine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCN1CCOCC1 DDSNBPYIVBWXGB-UHFFFAOYSA-N 0.000 claims 1
- SDTLVFOPJADHPB-UHFFFAOYSA-N 4-[2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]ethyl]morpholine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCOCC1 SDTLVFOPJADHPB-UHFFFAOYSA-N 0.000 claims 1
- XYOGGDREGYYWPA-UHFFFAOYSA-N 4-[3-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]propyl]morpholine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1CCCN1CCOCC1 XYOGGDREGYYWPA-UHFFFAOYSA-N 0.000 claims 1
- HGBLQEPBGGAPAW-UHFFFAOYSA-N 4-[3-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]propyl]morpholine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCCN1CCOCC1 HGBLQEPBGGAPAW-UHFFFAOYSA-N 0.000 claims 1
- ISQYTURYBKUOTA-UHFFFAOYSA-N 4-[3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]propyl]morpholine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1CCCN1CCOCC1 ISQYTURYBKUOTA-UHFFFAOYSA-N 0.000 claims 1
- KNOFIZHBESOPPI-UHFFFAOYSA-N 4-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)quinoline Chemical compound C1=CC=CC2=NC(C(F)(F)F)=CC(N3CCN(CC3)C=3C=4C(Br)=NNC=4N=CN=3)=C21 KNOFIZHBESOPPI-UHFFFAOYSA-N 0.000 claims 1
- TXVYVJXMZMPYMX-UHFFFAOYSA-N 4-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile Chemical compound C=12C(Br)=NNC2=NC=NC=1N(CC1)CCN1C1=CC=C(C#N)C=C1 TXVYVJXMZMPYMX-UHFFFAOYSA-N 0.000 claims 1
- LVOGLFHZHNTLSS-UHFFFAOYSA-N 4-[4-(3-bromo-5-chloro-2-methylphenyl)piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidin-6-amine Chemical compound CC1=C(Br)C=C(Cl)C=C1N1CCN(C=2C=3C=NNC=3N=C(N)N=2)CC1 LVOGLFHZHNTLSS-UHFFFAOYSA-N 0.000 claims 1
- BQQTTYBDFMEOIC-UHFFFAOYSA-N 4-[4-(3-chloro-5-methoxyphenyl)piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(OC)=C1 BQQTTYBDFMEOIC-UHFFFAOYSA-N 0.000 claims 1
- BVGJVMGHJXIGBN-UHFFFAOYSA-N 4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6,7-dimethoxyquinazoline Chemical compound COC1=C(OC)C=C2C(N3CCN(CC3)C=3N=CN=C4NN=C(C=34)CC)=NC=NC2=C1 BVGJVMGHJXIGBN-UHFFFAOYSA-N 0.000 claims 1
- WENXGABSSNOICL-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidin-6-amine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C=NNC=3N=C(N)N=2)CC1 WENXGABSSNOICL-UHFFFAOYSA-N 0.000 claims 1
- UWHHNRRWMAAGMX-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1,2,3,6-tetrahydropyridin-4-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4CCNCC=4)=NNC=3N=CN=2)CC1 UWHHNRRWMAAGMX-UHFFFAOYSA-N 0.000 claims 1
- RFBBUGWLRAJCHK-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=CC=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 RFBBUGWLRAJCHK-UHFFFAOYSA-N 0.000 claims 1
- WSQDXQLVVHANFN-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-chloropyridin-4-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C(=CN=CC=4)Cl)=NNC=3N=CN=2)CC1 WSQDXQLVVHANFN-UHFFFAOYSA-N 0.000 claims 1
- VVEVCMUDDUYAPL-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-fluoropyridin-4-yl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C(=CN=CC=4)F)=NNC=3N=CN=2)CC1 VVEVCMUDDUYAPL-UHFFFAOYSA-N 0.000 claims 1
- ZKJQPYPFCFCZHX-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound COC1=CC=CC(C=2C3=C(N4CCN(CC4)C=4C(=CC=C(Cl)C=4)C)N=CN=C3NN=2)=C1 ZKJQPYPFCFCZHX-UHFFFAOYSA-N 0.000 claims 1
- OFGPMXXPBQRGQG-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-enyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC=C(C)C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C OFGPMXXPBQRGQG-UHFFFAOYSA-N 0.000 claims 1
- BMZLXAUYUKVRBT-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-phenylmethoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(OCC=5C=CC=CC=5)C=CC=4)=NNC=3N=CN=2)CC1 BMZLXAUYUKVRBT-UHFFFAOYSA-N 0.000 claims 1
- WSDIKTCRDBJNEZ-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylpropyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(CCCN4CCCC4)=NNC=3N=CN=2)CC1 WSDIKTCRDBJNEZ-UHFFFAOYSA-N 0.000 claims 1
- WXIKPYIDNAJYKS-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-fluorophenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(F)=CC=4)=NNC=3N=CN=2)CC1 WXIKPYIDNAJYKS-UHFFFAOYSA-N 0.000 claims 1
- HEMUMKTZPWGNKZ-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 HEMUMKTZPWGNKZ-UHFFFAOYSA-N 0.000 claims 1
- JKYFXFLTMOYKHE-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylphenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 JKYFXFLTMOYKHE-UHFFFAOYSA-N 0.000 claims 1
- SABZWXMHVIATPL-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-phenoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(OC=5C=CC=CC=5)=CC=4)=NNC=3N=CN=2)CC1 SABZWXMHVIATPL-UHFFFAOYSA-N 0.000 claims 1
- WGLZMPRVECRUGN-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(piperidin-4-ylmethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(CC4CCNCC4)=NNC=3N=CN=2)CC1 WGLZMPRVECRUGN-UHFFFAOYSA-N 0.000 claims 1
- QZPJJGRIIWFHNP-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(piperidin-4-ylmethoxy)phenyl]-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(OCC5CCNCC5)=CC=4)=NNC=3N=CN=2)CC1 QZPJJGRIIWFHNP-UHFFFAOYSA-N 0.000 claims 1
- NNMOENYDTWNVJF-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(N4CCNCC4)=NNC=3N=CN=2)CC1 NNMOENYDTWNVJF-UHFFFAOYSA-N 0.000 claims 1
- LRXQPIKTVGCSCD-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-pyridin-4-yl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CN=CC=4)=NNC=3N=CN=2)CC1 LRXQPIKTVGCSCD-UHFFFAOYSA-N 0.000 claims 1
- BQVOBOKTPDRMQV-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-thiophen-2-yl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4SC=CC=4)=NNC=3N=CN=2)CC1 BQVOBOKTPDRMQV-UHFFFAOYSA-N 0.000 claims 1
- SFSIFSMOSDIXGP-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-n-phenyl-2h-pyrazolo[3,4-d]pyrimidin-3-amine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(NC=4C=CC=CC=4)=NNC=3N=CN=2)CC1 SFSIFSMOSDIXGP-UHFFFAOYSA-N 0.000 claims 1
- MXHFMCMHQFKAME-UHFFFAOYSA-N 4-[4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(C(F)(F)F)=CC=C1Cl MXHFMCMHQFKAME-UHFFFAOYSA-N 0.000 claims 1
- FVXRHCYOLHMKEG-UHFFFAOYSA-N 4-[4-[3-bromo-5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methylphenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(OCC(F)(CF)CF)=CC(Br)=C1C FVXRHCYOLHMKEG-UHFFFAOYSA-N 0.000 claims 1
- BWDRROCFMQDWRM-UHFFFAOYSA-N 4-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]benzonitrile Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(=CC=4)C#N)=NNC=3N=CN=2)CC1 BWDRROCFMQDWRM-UHFFFAOYSA-N 0.000 claims 1
- PHMKLEPFJAIHGK-UHFFFAOYSA-N 4-[4-[4-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(N2CCN(CC2)C=2C=3C=NNC=3N=CN=2)C=C1OCCN1CCCC1 PHMKLEPFJAIHGK-UHFFFAOYSA-N 0.000 claims 1
- FIBUNCPXQUWYHP-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCN1CCCCC1 FIBUNCPXQUWYHP-UHFFFAOYSA-N 0.000 claims 1
- JFIJGHSUNBWBAL-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCCC1 JFIJGHSUNBWBAL-UHFFFAOYSA-N 0.000 claims 1
- SWUHHIRFMYRIJB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C=NNC=3N=CN=2)C(C)=C1OCCN1CCCC1 SWUHHIRFMYRIJB-UHFFFAOYSA-N 0.000 claims 1
- UPRIVIWOZLARIH-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-(2-methylpropyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC(C)C)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 UPRIVIWOZLARIH-UHFFFAOYSA-N 0.000 claims 1
- BPGKERZGJLJMED-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCN1CCCC1 BPGKERZGJLJMED-UHFFFAOYSA-N 0.000 claims 1
- VAPICOZQFYVJCT-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 VAPICOZQFYVJCT-UHFFFAOYSA-N 0.000 claims 1
- WMDNCMBKBRUWNI-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 WMDNCMBKBRUWNI-UHFFFAOYSA-N 0.000 claims 1
- IXFLVBJXEDPMNN-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-propan-2-yl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(C(C)C)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 IXFLVBJXEDPMNN-UHFFFAOYSA-N 0.000 claims 1
- XBGWSDJSVVDITQ-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCCN1CCCCC1 XBGWSDJSVVDITQ-UHFFFAOYSA-N 0.000 claims 1
- HFMZMDXFDNLWCB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1CCCN1CCCCC1 HFMZMDXFDNLWCB-UHFFFAOYSA-N 0.000 claims 1
- CCMZHPLGQJCYTC-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1CCCN1CCCCC1 CCMZHPLGQJCYTC-UHFFFAOYSA-N 0.000 claims 1
- YNEHNQLNJHUVNL-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCCN1CCCC1 YNEHNQLNJHUVNL-UHFFFAOYSA-N 0.000 claims 1
- MAWNYUYBGKUWRX-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C=NNC=3N=CN=2)C(C)=C1CCCN1CCCC1 MAWNYUYBGKUWRX-UHFFFAOYSA-N 0.000 claims 1
- ASGJAACMIIQVBB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1CCCN1CCCC1 ASGJAACMIIQVBB-UHFFFAOYSA-N 0.000 claims 1
- KWKGHSHSXVOIQU-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1CCCN1CCCC1 KWKGHSHSXVOIQU-UHFFFAOYSA-N 0.000 claims 1
- LYIFKMWHZVCOEB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCC1COC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C LYIFKMWHZVCOEB-UHFFFAOYSA-N 0.000 claims 1
- XCOVTQGGVHMDFB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(1-methylpiperidin-4-yl)ethoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCC1CCN(C)CC1 XCOVTQGGVHMDFB-UHFFFAOYSA-N 0.000 claims 1
- MREHXQMHLRHSEM-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C MREHXQMHLRHSEM-UHFFFAOYSA-N 0.000 claims 1
- XCFTYDOZRKVXNM-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCN(C)CC1 XCFTYDOZRKVXNM-UHFFFAOYSA-N 0.000 claims 1
- NMYJCDPLLFGHEJ-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(C)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C NMYJCDPLLFGHEJ-UHFFFAOYSA-N 0.000 claims 1
- RHHDBYUITDSZOI-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCCN1CCN(C)CC1 RHHDBYUITDSZOI-UHFFFAOYSA-N 0.000 claims 1
- IEGMLOPFLQNVPN-UHFFFAOYSA-N 4-[4-[5-chloro-3-[2-(4-ethylpiperazin-1-yl)ethoxy]-2-methylphenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C IEGMLOPFLQNVPN-UHFFFAOYSA-N 0.000 claims 1
- DZFNNPOBVMURRI-UHFFFAOYSA-N 4-[4-[5-chloro-3-[2-(4-ethylpiperazin-1-yl)ethoxy]-2-methylphenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C DZFNNPOBVMURRI-UHFFFAOYSA-N 0.000 claims 1
- ORHSSASUVVWACH-UHFFFAOYSA-N 4-[4-[5-chloro-3-[3-(4-ethylpiperazin-1-yl)propoxy]-2-methylphenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C ORHSSASUVVWACH-UHFFFAOYSA-N 0.000 claims 1
- AFQIYWYPUWYCCT-UHFFFAOYSA-N 4-[4-[5-chloro-3-[3-(4-ethylpiperazin-1-yl)propoxy]-2-methylphenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C AFQIYWYPUWYCCT-UHFFFAOYSA-N 0.000 claims 1
- YCUQWQAJXMRFNN-UHFFFAOYSA-N 5-[2,3-difluoro-2-(fluoromethyl)propoxy]-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(OCC(F)(CF)CF)=CC=1NCCN1CCCC1 YCUQWQAJXMRFNN-UHFFFAOYSA-N 0.000 claims 1
- JTLPCDMHGTVANG-UHFFFAOYSA-N 5-chloro-2-methyl-3-[4-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 JTLPCDMHGTVANG-UHFFFAOYSA-N 0.000 claims 1
- CABOYHXJYNGXSR-UHFFFAOYSA-N 5-chloro-2-methyl-3-[4-(3-propan-2-yl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=12C(C(C)C)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1NCCN1CCCC1 CABOYHXJYNGXSR-UHFFFAOYSA-N 0.000 claims 1
- WVSOMLBCFGPONC-UHFFFAOYSA-N 5-chloro-2-methyl-3-[4-[3-(2-methylpropyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C=12C(CC(C)C)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1NCCN1CCCC1 WVSOMLBCFGPONC-UHFFFAOYSA-N 0.000 claims 1
- ICZBXKGLNSAERJ-UHFFFAOYSA-N 5-chloro-3-[4-(3-cyclopropyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(C4CC4)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 ICZBXKGLNSAERJ-UHFFFAOYSA-N 0.000 claims 1
- IPSGJJMTWOHXNA-UHFFFAOYSA-N 5-fluoro-2-methyl-n-(2-pyrrolidin-1-ylethyl)-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]aniline Chemical compound C1=C(F)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1NCCN1CCCC1 IPSGJJMTWOHXNA-UHFFFAOYSA-N 0.000 claims 1
- FUZOXHWXAYGCHT-UHFFFAOYSA-N 6-[2-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrimidin-4-yl]-4h-1,4-benzoxazin-3-one Chemical compound O1CC(=O)NC2=CC(C=3C=CN=C(N=3)N3CCN(CC3)C=3N=CN=C4NN=C(C=34)Br)=CC=C21 FUZOXHWXAYGCHT-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- FTDNIAMWPZPKLR-UHFFFAOYSA-N [1-(3-chlorophenyl)-4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2-yl]methanol Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1CO)CCN1C1=CC=CC(Cl)=C1 FTDNIAMWPZPKLR-UHFFFAOYSA-N 0.000 claims 1
- QMSVBRCEGLXJLU-UHFFFAOYSA-N [3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-phenylmethanone Chemical compound C1=C(C(=O)C=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 QMSVBRCEGLXJLU-UHFFFAOYSA-N 0.000 claims 1
- VQXJMCMQYVZVKB-UHFFFAOYSA-N [3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-pyrrolidin-1-ylmethanone Chemical compound C1=C(C(=O)N2CCCC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 VQXJMCMQYVZVKB-UHFFFAOYSA-N 0.000 claims 1
- KXAKPLZFCFFJSW-UHFFFAOYSA-N [3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]methanol Chemical compound C1=C(CO)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 KXAKPLZFCFFJSW-UHFFFAOYSA-N 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- PRGBKZSNTIVFOY-UHFFFAOYSA-N methyl 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 PRGBKZSNTIVFOY-UHFFFAOYSA-N 0.000 claims 1
- DUAMSJLUECLRIC-UHFFFAOYSA-N methyl 3-bromo-5-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 DUAMSJLUECLRIC-UHFFFAOYSA-N 0.000 claims 1
- USXFGRUIDBDIFV-UHFFFAOYSA-N n,n-diethyl-2-[3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenoxy]ethanamine Chemical compound CCN(CC)CCOC1=CC=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1 USXFGRUIDBDIFV-UHFFFAOYSA-N 0.000 claims 1
- PMYOVPDVCABZJD-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)phenyl]-n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCNC1=CC(OCC(C)C)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C PMYOVPDVCABZJD-UHFFFAOYSA-N 0.000 claims 1
- OJFLWUQRQWXTTQ-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)phenyl]-n',n'-dimethylethane-1,2-diamine Chemical compound CC(C)COC1=CC(NCCN(C)C)=C(C)C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1 OJFLWUQRQWXTTQ-UHFFFAOYSA-N 0.000 claims 1
- GKIKAXFTSTUNIZ-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-fluoro-2-methylpropoxy)-2-methylphenyl]-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNC1=CC(OCC(C)(C)F)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C GKIKAXFTSTUNIZ-UHFFFAOYSA-N 0.000 claims 1
- JQNWZNUXLMFBJM-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[2,3-difluoro-2-(fluoromethyl)propoxy]-2-methylphenyl]-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNC1=CC(OCC(F)(CF)CF)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C JQNWZNUXLMFBJM-UHFFFAOYSA-N 0.000 claims 1
- HWKCACYJOZRVLP-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C HWKCACYJOZRVLP-UHFFFAOYSA-N 0.000 claims 1
- GPNUVUGMFDKAJH-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C GPNUVUGMFDKAJH-UHFFFAOYSA-N 0.000 claims 1
- IBCUWWNXHJWZJO-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-n'-methyl-n'-propan-2-ylethane-1,2-diamine Chemical compound CC(C)N(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C IBCUWWNXHJWZJO-UHFFFAOYSA-N 0.000 claims 1
- CXRSSJQLJNMMKA-UHFFFAOYSA-N n-[4-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 CXRSSJQLJNMMKA-UHFFFAOYSA-N 0.000 claims 1
- ITLDDBHNZHKWPN-UHFFFAOYSA-N n-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenyl]-n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C ITLDDBHNZHKWPN-UHFFFAOYSA-N 0.000 claims 1
- BTHYNSZFAHGSOX-UHFFFAOYSA-N n-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenyl]-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C BTHYNSZFAHGSOX-UHFFFAOYSA-N 0.000 claims 1
- ACXREQVXILYMKB-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n',n'-dimethylethane-1,2-diamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(NCCN(C)C)=C1C ACXREQVXILYMKB-UHFFFAOYSA-N 0.000 claims 1
- SPRYQHWIDYANOC-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n'-ethyl-n'-methylethane-1,2-diamine Chemical compound CCN(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C SPRYQHWIDYANOC-UHFFFAOYSA-N 0.000 claims 1
- OBOJJQBWMAPELI-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n'-methyl-n'-propan-2-ylethane-1,2-diamine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(NCCN(C)C(C)C)=C1C OBOJJQBWMAPELI-UHFFFAOYSA-N 0.000 claims 1
- LKQUCICFTHBFAL-UHFFFAOYSA-N n-benzylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NCC1=CC=CC=C1 LKQUCICFTHBFAL-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 379
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 374
- 238000005481 NMR spectroscopy Methods 0.000 description 304
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 140
- 235000019439 ethyl acetate Nutrition 0.000 description 128
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 108
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 91
- 239000000243 solution Substances 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- 239000007787 solid Substances 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 77
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 69
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 66
- 229910052938 sodium sulfate Inorganic materials 0.000 description 65
- 235000011152 sodium sulphate Nutrition 0.000 description 65
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 63
- 238000004440 column chromatography Methods 0.000 description 61
- 239000000377 silicon dioxide Substances 0.000 description 60
- 239000012267 brine Substances 0.000 description 55
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 55
- 239000012044 organic layer Substances 0.000 description 54
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 43
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 125000001072 heteroaryl group Chemical group 0.000 description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- 239000003153 chemical reaction reagent Substances 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 30
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 29
- 230000027455 binding Effects 0.000 description 27
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 25
- 229910052799 carbon Inorganic materials 0.000 description 25
- 239000010410 layer Substances 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 125000005843 halogen group Chemical group 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 18
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- 229910000024 caesium carbonate Inorganic materials 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 238000004007 reversed phase HPLC Methods 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 108020001756 ligand binding domains Proteins 0.000 description 11
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 206010039491 Sarcoma Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000004043 oxo group Chemical group O=* 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 125000001118 alkylidene group Chemical group 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 238000005094 computer simulation Methods 0.000 description 7
- 206010016629 fibroma Diseases 0.000 description 7
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- FVDJRHNUZNLRJC-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)piperazine Chemical compound CC1=CC=C(Cl)C=C1N1CCNCC1 FVDJRHNUZNLRJC-UHFFFAOYSA-N 0.000 description 6
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 6
- QIXXACAFRCQPFS-UHFFFAOYSA-N 6-[4-(3-chlorophenyl)piperazin-1-yl]-7h-purine Chemical class ClC1=CC=CC(N2CCN(CC2)C=2C=3NC=NC=3N=CN=2)=C1 QIXXACAFRCQPFS-UHFFFAOYSA-N 0.000 description 6
- MBRQCVJHJOVNLO-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)piperazin-1-yl]-7h-purine Chemical compound C1=CC(F)=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 MBRQCVJHJOVNLO-UHFFFAOYSA-N 0.000 description 6
- ICAARADRKONXBF-UHFFFAOYSA-N 6-[4-(4-methoxyphenyl)piperazin-1-yl]-7h-purine Chemical class C1=CC(OC)=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 ICAARADRKONXBF-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 238000004590 computer program Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000005415 substituted alkoxy group Chemical group 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- LCGMENDABLGZBC-UHFFFAOYSA-N 4-[4-(3-chlorophenyl)piperazin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=CC=CC(N2CCN(CC2)C=2C=3C=NNC=3N=CN=2)=C1 LCGMENDABLGZBC-UHFFFAOYSA-N 0.000 description 5
- WAIMQUPDNQRLKD-UHFFFAOYSA-N 4-chloro-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(CC)=NNC2=N1 WAIMQUPDNQRLKD-UHFFFAOYSA-N 0.000 description 5
- HCGWOUNUNZPMMV-UHFFFAOYSA-N 6-(4-pyrimidin-2-ylpiperazin-1-yl)-7h-purine Chemical compound C1CN(C=2C=3NC=NC=3N=CN=2)CCN1C1=NC=CC=N1 HCGWOUNUNZPMMV-UHFFFAOYSA-N 0.000 description 5
- SSXSBIJYAWHOSQ-UHFFFAOYSA-N 6-[4-(2,5-dimethylphenyl)piperazin-1-yl]-7h-purine Chemical compound CC1=CC=C(C)C(N2CCN(CC2)C=2C=3NC=NC=3N=CN=2)=C1 SSXSBIJYAWHOSQ-UHFFFAOYSA-N 0.000 description 5
- ZMJKIUCPJALXPF-UHFFFAOYSA-N 6-[4-(2-fluorophenyl)piperazin-1-yl]-7h-purine Chemical class FC1=CC=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 ZMJKIUCPJALXPF-UHFFFAOYSA-N 0.000 description 5
- QVBFELMJIOAJLK-UHFFFAOYSA-N 6-[4-(3,4-dichlorophenyl)piperazin-1-yl]-7h-purine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 QVBFELMJIOAJLK-UHFFFAOYSA-N 0.000 description 5
- AQKCWTXVJVQGDX-UHFFFAOYSA-N 6-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-7h-purine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC2)C=2C=3NC=NC=3N=CN=2)=C1 AQKCWTXVJVQGDX-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- WAVOFQCBZGBMFX-UHFFFAOYSA-N methanesulfonic acid;6-[4-(2-methoxyphenyl)piperazin-1-yl]-7h-purine Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.COC1=CC=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 WAVOFQCBZGBMFX-UHFFFAOYSA-N 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 5
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 4
- KDYPEARPZJFJBV-UHFFFAOYSA-N 6-[4-(2-chlorophenyl)piperazin-1-yl]-7h-purine Chemical compound ClC1=CC=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 KDYPEARPZJFJBV-UHFFFAOYSA-N 0.000 description 4
- KWLXRQFZEOGTIH-UHFFFAOYSA-N 6-[4-(2-methoxyphenyl)piperazin-1-yl]-7h-purine Chemical compound COC1=CC=CC=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 KWLXRQFZEOGTIH-UHFFFAOYSA-N 0.000 description 4
- LTKVADSFDKAFCU-UHFFFAOYSA-N 6-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-7h-purine Chemical compound FC(F)(F)C1=CC=CN=C1N1CCN(C=2C=3NC=NC=3N=CN=2)CC1 LTKVADSFDKAFCU-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 229910014265 BrCl Inorganic materials 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 150000001721 carbon Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 3
- JHIWJXNUTCUPEF-UHFFFAOYSA-N 6-(4-phenylpiperazin-1-yl)-7h-purine Chemical compound C1CN(C=2C=3NC=NC=3N=CN=2)CCN1C1=CC=CC=C1 JHIWJXNUTCUPEF-UHFFFAOYSA-N 0.000 description 3
- WTNDAPKCZINZQI-UHFFFAOYSA-N 6-(4-pyridin-2-ylpiperazin-1-yl)-7h-purine Chemical compound C1CN(C=2C=3NC=NC=3N=CN=2)CCN1C1=CC=CC=N1 WTNDAPKCZINZQI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 208000008798 osteoma Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 3
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- ANSSPNJBAYQWRK-UHFFFAOYSA-N (3-bromo-5-chloro-2-methoxyphenyl)methanol Chemical compound COC1=C(Br)C=C(Cl)C=C1CO ANSSPNJBAYQWRK-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- HCSPSOHASPVBNM-UHFFFAOYSA-N 1,3-dibromo-5-(2-ethylbutoxy)-2-methylbenzene Chemical compound CCC(CC)COC1=CC(Br)=C(C)C(Br)=C1 HCSPSOHASPVBNM-UHFFFAOYSA-N 0.000 description 2
- YWTLSQDOONKMOJ-UHFFFAOYSA-N 1,3-dibromo-5-ethylsulfonyl-2-methylbenzene Chemical compound CCS(=O)(=O)C1=CC(Br)=C(C)C(Br)=C1 YWTLSQDOONKMOJ-UHFFFAOYSA-N 0.000 description 2
- LZWVTQKAHFBVJA-UHFFFAOYSA-N 1,3-dichloro-5-phenylmethoxybenzene Chemical compound ClC1=CC(Cl)=CC(OCC=2C=CC=CC=2)=C1 LZWVTQKAHFBVJA-UHFFFAOYSA-N 0.000 description 2
- LLKMJMQVKKJDAT-UHFFFAOYSA-N 1-(2-methyl-3-phenylmethoxyphenyl)piperazine Chemical compound C1=CC=C(N2CCNCC2)C(C)=C1OCC1=CC=CC=C1 LLKMJMQVKKJDAT-UHFFFAOYSA-N 0.000 description 2
- GMWFVNNUKZUKHT-UHFFFAOYSA-N 1-(3-chloro-4-phenylmethoxyphenyl)piperazine Chemical compound ClC1=CC(N2CCNCC2)=CC=C1OCC1=CC=CC=C1 GMWFVNNUKZUKHT-UHFFFAOYSA-N 0.000 description 2
- YKCMSKWIWGCSLG-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(Cl)=C1 YKCMSKWIWGCSLG-UHFFFAOYSA-N 0.000 description 2
- AYGSSBGDRWWJRM-UHFFFAOYSA-N 1-(5-chloro-2-methyl-4-phenylmethoxyphenyl)piperazine Chemical compound ClC=1C=C(N2CCNCC2)C(C)=CC=1OCC1=CC=CC=C1 AYGSSBGDRWWJRM-UHFFFAOYSA-N 0.000 description 2
- UXKTVCRKUQMRIM-UHFFFAOYSA-N 1-(5-chloro-3-iodo-2-methylphenyl)piperazine Chemical compound CC1=C(I)C=C(Cl)C=C1N1CCNCC1 UXKTVCRKUQMRIM-UHFFFAOYSA-N 0.000 description 2
- VNSZFUHIYFCNBA-UHFFFAOYSA-N 1-[3-piperazin-1-yl-5-(2-pyrrolidin-1-ylethylamino)phenyl]butan-1-one;hydrochloride Chemical compound Cl.C=1C(N2CCNCC2)=CC(C(=O)CCC)=CC=1NCCN1CCCC1 VNSZFUHIYFCNBA-UHFFFAOYSA-N 0.000 description 2
- GNJFDVMDZRSYSH-UHFFFAOYSA-N 1-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1CCCN1CCCC1 GNJFDVMDZRSYSH-UHFFFAOYSA-N 0.000 description 2
- HHQMROZCVARUAG-UHFFFAOYSA-N 1-bromopropane;magnesium Chemical compound [Mg].CCCBr HHQMROZCVARUAG-UHFFFAOYSA-N 0.000 description 2
- LGJGKSIGZJWWOU-UHFFFAOYSA-N 1-chloro-4-methyl-5-nitroso-2-phenylmethoxybenzene Chemical compound C1=C(N=O)C(C)=CC(OCC=2C=CC=CC=2)=C1Cl LGJGKSIGZJWWOU-UHFFFAOYSA-N 0.000 description 2
- IYFXPOWQFWHFNO-UHFFFAOYSA-N 1-chloro-4-methyl-6-phenylmethoxycyclohexa-2,4-dien-1-amine Chemical compound NC1(Cl)C=CC(C)=CC1OCC1=CC=CC=C1 IYFXPOWQFWHFNO-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LRRBSBYKUDBUCC-UHFFFAOYSA-N 1-tert-butyl-4-chloro-3-(trifluoromethyl)pyrazolo[3,4-d]pyrimidine Chemical compound N1=CN=C2N(C(C)(C)C)N=C(C(F)(F)F)C2=C1Cl LRRBSBYKUDBUCC-UHFFFAOYSA-N 0.000 description 2
- JQNOTRRYTBGTRR-UHFFFAOYSA-N 2-(1-hydroxybutylidene)propanedinitrile Chemical compound CCCC(O)=C(C#N)C#N JQNOTRRYTBGTRR-UHFFFAOYSA-N 0.000 description 2
- HNNJMJWOSXHEJJ-UHFFFAOYSA-N 2-(1-methoxybutylidene)propanedinitrile Chemical compound CCCC(OC)=C(C#N)C#N HNNJMJWOSXHEJJ-UHFFFAOYSA-N 0.000 description 2
- VEXSEQYCQCWPKC-UHFFFAOYSA-N 2-(3-bromo-5-chloro-2-methoxyphenoxy)-n,n-dimethylethanamine Chemical compound COC1=C(Br)C=C(Cl)C=C1OCCN(C)C VEXSEQYCQCWPKC-UHFFFAOYSA-N 0.000 description 2
- AHGXQMBEGNIIFZ-UHFFFAOYSA-N 2-(5-chloro-2-methoxy-3-piperazin-1-ylphenoxy)-n,n-dimethylethanamine Chemical compound COC1=C(OCCN(C)C)C=C(Cl)C=C1N1CCNCC1 AHGXQMBEGNIIFZ-UHFFFAOYSA-N 0.000 description 2
- UTKFOTINIHYUNG-UHFFFAOYSA-N 2-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)-n,n-dimethylethanamine;hydrochloride Chemical compound Cl.CN(C)CCOC1=CC(Cl)=CC(N2CCNCC2)=C1C UTKFOTINIHYUNG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GQRCTVZXQLUDBU-UHFFFAOYSA-N 2-[1-methoxy-2-(2-methoxyethoxy)ethylidene]propanedinitrile Chemical compound COCCOCC(OC)=C(C#N)C#N GQRCTVZXQLUDBU-UHFFFAOYSA-N 0.000 description 2
- FXECOYYRPDGOQB-UHFFFAOYSA-N 2-chloro-4-piperazin-1-ylphenol Chemical compound C1=C(Cl)C(O)=CC=C1N1CCNCC1 FXECOYYRPDGOQB-UHFFFAOYSA-N 0.000 description 2
- GRDWXOLMJKVABV-UHFFFAOYSA-N 2-chloro-5-methyl-4-piperazin-1-ylphenol Chemical compound CC1=CC(O)=C(Cl)C=C1N1CCNCC1 GRDWXOLMJKVABV-UHFFFAOYSA-N 0.000 description 2
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 2
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 2
- PBSZHNXXFIYDBU-UHFFFAOYSA-N 2-methyl-1-nitro-3-phenylmethoxybenzene Chemical compound C1=CC=C([N+]([O-])=O)C(C)=C1OCC1=CC=CC=C1 PBSZHNXXFIYDBU-UHFFFAOYSA-N 0.000 description 2
- IHMXLABJHKKMTC-UHFFFAOYSA-N 2-methyl-3-phenylmethoxyaniline Chemical compound CC1=C(N)C=CC=C1OCC1=CC=CC=C1 IHMXLABJHKKMTC-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- LOWZPOSKBWZMFN-UHFFFAOYSA-N 3,5-dibromo-4-methylbenzenethiol Chemical compound CC1=C(Br)C=C(S)C=C1Br LOWZPOSKBWZMFN-UHFFFAOYSA-N 0.000 description 2
- SVMOURXLHJYDSL-UHFFFAOYSA-N 3-(2-methoxyethoxymethyl)-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=NC(O)=C2C(COCCOC)=NNC2=N1 SVMOURXLHJYDSL-UHFFFAOYSA-N 0.000 description 2
- YAZKUAAGEAVPOX-UHFFFAOYSA-N 3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-n,n-diethylpropan-1-amine;hydrochloride Chemical compound Cl.CCN(CC)CCCC1=CC(Cl)=CC(N2CCNCC2)=C1C YAZKUAAGEAVPOX-UHFFFAOYSA-N 0.000 description 2
- WRNMWJANSIWPSO-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-ethylbutoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCC(CC)CC)=CC=1NCCN1CCCC1 WRNMWJANSIWPSO-UHFFFAOYSA-N 0.000 description 2
- PIKTZPAJHCXGGM-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]propan-1-ol;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(CCCO)NN=C3N=CN=2)CC1 PIKTZPAJHCXGGM-UHFFFAOYSA-N 0.000 description 2
- QFXGCRQDTNRNMY-UHFFFAOYSA-N 3-amino-5-(2-methoxyethoxymethyl)-1h-pyrazole-4-carbonitrile Chemical compound COCCOCC1=NNC(N)=C1C#N QFXGCRQDTNRNMY-UHFFFAOYSA-N 0.000 description 2
- YWRKFBPYSYYYMN-UHFFFAOYSA-N 3-amino-5-propyl-1h-pyrazole-4-carbonitrile Chemical compound CCCC1=NNC(N)=C1C#N YWRKFBPYSYYYMN-UHFFFAOYSA-N 0.000 description 2
- DGAWZKMBSUKIKI-UHFFFAOYSA-N 3-bromo-4-methyl-5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]benzoic acid Chemical compound CC1=C(Br)C=C(C(O)=O)C=C1N1CCN(C(=O)OC(C)(C)C)CC1 DGAWZKMBSUKIKI-UHFFFAOYSA-N 0.000 description 2
- LVLKZFYISQEUFL-UHFFFAOYSA-N 3-bromo-4-methyl-n-phenyl-5-piperazin-1-ylbenzamide;hydrochloride Chemical compound Cl.CC1=C(Br)C=C(C(=O)NC=2C=CC=CC=2)C=C1N1CCNCC1 LVLKZFYISQEUFL-UHFFFAOYSA-N 0.000 description 2
- WMHPXUMZJOUCSK-UHFFFAOYSA-N 3-bromo-5-chloro-2-methoxybenzaldehyde Chemical compound COC1=C(Br)C=C(Cl)C=C1C=O WMHPXUMZJOUCSK-UHFFFAOYSA-N 0.000 description 2
- ZCIWNGLMYMAPGX-UHFFFAOYSA-N 3-bromo-5-chloro-2-methoxyphenol Chemical compound COC1=C(O)C=C(Cl)C=C1Br ZCIWNGLMYMAPGX-UHFFFAOYSA-N 0.000 description 2
- PTKLDNPKLLKELG-UHFFFAOYSA-N 3-chloro-5-piperazin-1-ylphenol Chemical compound OC1=CC(Cl)=CC(N2CCNCC2)=C1 PTKLDNPKLLKELG-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- XFQRTMDBKVVAHL-UHFFFAOYSA-N 3-propyl-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=NC(O)=C2C(CCC)=NNC2=N1 XFQRTMDBKVVAHL-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RGNRJRKMSRGMHQ-UHFFFAOYSA-N 4-[2-(2-chloro-4-piperazin-1-ylphenoxy)ethyl]morpholine;hydrochloride Chemical compound Cl.ClC1=CC(N2CCNCC2)=CC=C1OCCN1CCOCC1 RGNRJRKMSRGMHQ-UHFFFAOYSA-N 0.000 description 2
- ZWXDAGFKCZMYTQ-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(N4CCNCC4)=NNC=3N=CN=2)CC1 ZWXDAGFKCZMYTQ-UHFFFAOYSA-N 0.000 description 2
- RUVDUIQMBVBZFS-UHFFFAOYSA-N 4-bromo-2-chloro-1-phenylmethoxybenzene Chemical compound ClC1=CC(Br)=CC=C1OCC1=CC=CC=C1 RUVDUIQMBVBZFS-UHFFFAOYSA-N 0.000 description 2
- IOMPADPEBLABRM-UHFFFAOYSA-N 4-chloro-3-(2-methoxyethoxymethyl)-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(COCCOC)=NNC2=N1 IOMPADPEBLABRM-UHFFFAOYSA-N 0.000 description 2
- XFDFMJYQFBHDMF-UHFFFAOYSA-N 4-chloro-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(C)=NNC2=N1 XFDFMJYQFBHDMF-UHFFFAOYSA-N 0.000 description 2
- ZUCMUUMUEOALJU-UHFFFAOYSA-N 4-chloro-3-phenyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2NN=C1C1=CC=CC=C1 ZUCMUUMUEOALJU-UHFFFAOYSA-N 0.000 description 2
- FMJNJDVLTSSZHB-UHFFFAOYSA-N 4-chloro-3-propyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(CCC)=NNC2=N1 FMJNJDVLTSSZHB-UHFFFAOYSA-N 0.000 description 2
- PMZODXFLGOEQQR-UHFFFAOYSA-N 4-chloro-n-phenyl-2h-pyrazolo[3,4-d]pyrimidin-3-amine Chemical compound C1=2C(Cl)=NC=NC=2NN=C1NC1=CC=CC=C1 PMZODXFLGOEQQR-UHFFFAOYSA-N 0.000 description 2
- FUQMYXHATNHEBU-UHFFFAOYSA-N 4-methyl-3-[2-pyrrolidin-1-ylethyl-(2,2,2-trifluoroacetyl)amino]-5-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]benzoyl fluoride Chemical compound CC1=C(N(CCN2CCCC2)C(=O)C(F)(F)F)C=C(C(F)=O)C=C1N1CCN(C(=O)C(F)(F)F)CC1 FUQMYXHATNHEBU-UHFFFAOYSA-N 0.000 description 2
- GEBSWXYSAYUCIK-UHFFFAOYSA-N 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(CCC(C)(C)C)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 GEBSWXYSAYUCIK-UHFFFAOYSA-N 0.000 description 2
- ICDORFVGVBPTPQ-UHFFFAOYSA-N 5-(3,5-dibromo-4-methylphenyl)-3-phenyl-1,2,4-oxadiazole Chemical compound C1=C(Br)C(C)=C(Br)C=C1C1=NC(C=2C=CC=CC=2)=NO1 ICDORFVGVBPTPQ-UHFFFAOYSA-N 0.000 description 2
- HQLVDQVRDDXAPF-UHFFFAOYSA-N 5-chloro-3-iodo-2-methylaniline Chemical compound CC1=C(N)C=C(Cl)C=C1I HQLVDQVRDDXAPF-UHFFFAOYSA-N 0.000 description 2
- OCEQBYVMMNGTIV-UHFFFAOYSA-N 6-methyl-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound O=C1N=C(C)N=C2NNC=C21 OCEQBYVMMNGTIV-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- YWSPAMZYNRZEPH-UHFFFAOYSA-N CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)Cl)CCC=O Chemical compound CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)Cl)CCC=O YWSPAMZYNRZEPH-UHFFFAOYSA-N 0.000 description 2
- HMKHIMBBYPWFNR-UHFFFAOYSA-N CC1=CC(=C(C=C1OC(=O)N2CCNCC2)Cl)O Chemical compound CC1=CC(=C(C=C1OC(=O)N2CCNCC2)Cl)O HMKHIMBBYPWFNR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- OXNXUKTUQPCUSV-UHFFFAOYSA-N S-(3,5-dibromo-4-methylphenyl) N,N-dimethylcarbamothioate Chemical compound CN(C)C(=O)SC1=CC(Br)=C(C)C(Br)=C1 OXNXUKTUQPCUSV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WZORUWZCRWIYSR-UHFFFAOYSA-N benzyl 3,5-dibromo-4-methylbenzoate Chemical compound C1=C(Br)C(C)=C(Br)C=C1C(=O)OCC1=CC=CC=C1 WZORUWZCRWIYSR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- ZPSVEMAMMZJGAE-UHFFFAOYSA-N o-(3,5-dibromo-4-methylphenyl) n,n-dimethylcarbamothioate Chemical compound CN(C)C(=S)OC1=CC(Br)=C(C)C(Br)=C1 ZPSVEMAMMZJGAE-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000005551 pyridylene group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- AJDDAQMHYYXFRS-UHFFFAOYSA-N tert-butyl 4-(3-chloro-4-hydroxyphenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(O)C(Cl)=C1 AJDDAQMHYYXFRS-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GCJYUUCHJZQFLE-JQWIXIFHSA-N (2s)-2-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-n-[2-[2-(1h-imidazol-5-yl)ethylamino]acetyl]pentanediamide Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NC(=O)CNCCC1=CN=CN1 GCJYUUCHJZQFLE-JQWIXIFHSA-N 0.000 description 1
- YYXFJSDMOVHLMJ-UHFFFAOYSA-N (4-hydroxyphenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(O)C=C1 YYXFJSDMOVHLMJ-UHFFFAOYSA-N 0.000 description 1
- 239000001211 (E)-4-phenylbut-3-en-2-one Substances 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PHWHUBAFWLAZGF-FXRZFVDSSA-N (e)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(\C=C\C(O)=O)NN=C3N=CN=2)CC1 PHWHUBAFWLAZGF-FXRZFVDSSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- XLOVPKCQAPHUKK-UHFFFAOYSA-N 1,2,3,4,4a,5,8,8a-octahydronaphthalene Chemical compound C1C=CCC2CCCCC21 XLOVPKCQAPHUKK-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZROTYBDROASODD-UHFFFAOYSA-N 1,3-dibromo-5-ethylsulfanyl-2-methylbenzene Chemical compound CCSC1=CC(Br)=C(C)C(Br)=C1 ZROTYBDROASODD-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- CZZKIHOJCVOFHG-UHFFFAOYSA-N 1-(3-bromo-2-chloro-5-fluorophenyl)piperazine Chemical compound FC1=CC(Br)=C(Cl)C(N2CCNCC2)=C1 CZZKIHOJCVOFHG-UHFFFAOYSA-N 0.000 description 1
- RLTQWHLFGHJVFI-UHFFFAOYSA-N 1-(3-chloro-5-methoxyphenyl)piperazine Chemical compound COC1=CC(Cl)=CC(N2CCNCC2)=C1 RLTQWHLFGHJVFI-UHFFFAOYSA-N 0.000 description 1
- FUSRAMJWPKVNRA-UHFFFAOYSA-N 1-(3-chlorophenyl)-1,4-diazepane Chemical compound ClC1=CC=CC(N2CCNCCC2)=C1 FUSRAMJWPKVNRA-UHFFFAOYSA-N 0.000 description 1
- ZXDSDMHARDHNNZ-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)-n-methylpiperazine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=12C(CC)=NNC2=NC=NC=1N(CC1C(=O)NC)CCN1C1=CC=CC(Cl)=C1 ZXDSDMHARDHNNZ-UHFFFAOYSA-N 0.000 description 1
- OHIRPXMQOZVSBD-UHFFFAOYSA-N 1-(3-chlorophenyl)-n-(1-methylpiperidin-4-yl)piperazine-2-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1N(C=2C=C(Cl)C=CC=2)CCNC1 OHIRPXMQOZVSBD-UHFFFAOYSA-N 0.000 description 1
- BSMMCZCMFLVTSV-UHFFFAOYSA-N 1-(3-chlorophenyl)-n-[2-(dimethylamino)ethyl]piperazine-2-carboxamide Chemical compound CN(C)CCNC(=O)C1CNCCN1C1=CC=CC(Cl)=C1 BSMMCZCMFLVTSV-UHFFFAOYSA-N 0.000 description 1
- HLDYTCJMGQUHOX-UHFFFAOYSA-N 1-(3-chlorophenyl)-n-methylpiperazine-2-carboxamide Chemical compound CNC(=O)C1CNCCN1C1=CC=CC(Cl)=C1 HLDYTCJMGQUHOX-UHFFFAOYSA-N 0.000 description 1
- RDTAAIKRENMWAE-UHFFFAOYSA-N 1-(5-chloro-3-methoxy-2-methylphenyl)piperazine Chemical compound COC1=CC(Cl)=CC(N2CCNCC2)=C1C RDTAAIKRENMWAE-UHFFFAOYSA-N 0.000 description 1
- UTJQWTYCZMVNGD-UHFFFAOYSA-N 1-(5-chloro-4-methoxy-2-methylphenyl)piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C(OC)=CC(C)=C1N1CCNCC1 UTJQWTYCZMVNGD-UHFFFAOYSA-N 0.000 description 1
- VLZRARREIQDNHX-UHFFFAOYSA-N 1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidine Chemical compound O1CCCCC1N1C2=NC=NC=C2C=N1 VLZRARREIQDNHX-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- FNSRDZSZLGZKCM-UHFFFAOYSA-N 1-[2-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)ethyl]-4-ethylpiperazine Chemical compound C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCNCC2)=C1C FNSRDZSZLGZKCM-UHFFFAOYSA-N 0.000 description 1
- LGNQJWUDGZGYQN-UHFFFAOYSA-N 1-[2-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)ethyl]-4-methylpiperazine;hydrochloride Chemical compound Cl.C1CN(C)CCN1CCOC1=CC(Cl)=CC(N2CCNCC2)=C1C LGNQJWUDGZGYQN-UHFFFAOYSA-N 0.000 description 1
- MEFLKSADQOHPFZ-UHFFFAOYSA-N 1-[3-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)propyl]-4-ethylpiperazine Chemical compound C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCNCC2)=C1C MEFLKSADQOHPFZ-UHFFFAOYSA-N 0.000 description 1
- SVQBXJZDAGXPOT-UHFFFAOYSA-N 1-[3-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)propyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1CCCOC1=CC(Cl)=CC(N2CCNCC2)=C1C SVQBXJZDAGXPOT-UHFFFAOYSA-N 0.000 description 1
- QNIHNXZWIZTTCG-UHFFFAOYSA-N 1-[3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)propyl]-4-methylpiperazine;hydrochloride Chemical compound Cl.C1CN(C)CCN1CCCC1=CC(Cl)=CC(N2CCNCC2)=C1C QNIHNXZWIZTTCG-UHFFFAOYSA-N 0.000 description 1
- KAYXZTXFDYAUHP-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-4,4,4-trifluorobutan-1-one;hydrochloride Chemical compound Cl.C1=C(C(=O)CCC(F)(F)F)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 KAYXZTXFDYAUHP-UHFFFAOYSA-N 0.000 description 1
- OYECUJHTGCCYCS-UHFFFAOYSA-N 1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]ethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)C)=CC=1NCCN1CCCC1 OYECUJHTGCCYCS-UHFFFAOYSA-N 0.000 description 1
- ACSPARFTZCIAPK-UHFFFAOYSA-N 1-[4-methyl-3-piperazin-1-yl-5-(2-pyrrolidin-1-ylethylamino)phenyl]pentan-1-one;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(C(=O)CCCC)=CC=1NCCN1CCCC1 ACSPARFTZCIAPK-UHFFFAOYSA-N 0.000 description 1
- ZWAHUEXJZPIPFV-UHFFFAOYSA-N 1-[4-methyl-3-piperazin-1-yl-5-(2-pyrrolidin-1-ylethylamino)phenyl]propan-1-one;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(C(=O)CC)=CC=1NCCN1CCCC1 ZWAHUEXJZPIPFV-UHFFFAOYSA-N 0.000 description 1
- FHCHAWMBEYOCHR-UHFFFAOYSA-N 1-[5-chloro-2-methyl-3-(2-piperidin-1-ylethoxy)phenyl]piperazine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1OCCN1CCCCC1 FHCHAWMBEYOCHR-UHFFFAOYSA-N 0.000 description 1
- MBTCMEMTPCBHQG-UHFFFAOYSA-N 1-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1OCCN1CCCC1 MBTCMEMTPCBHQG-UHFFFAOYSA-N 0.000 description 1
- QZGJRDFHUSXJMZ-UHFFFAOYSA-N 1-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropoxy)phenyl]piperazine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1OCCCN1CCCCC1 QZGJRDFHUSXJMZ-UHFFFAOYSA-N 0.000 description 1
- HMKHZGQQZUYGOX-UHFFFAOYSA-N 1-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropoxy)phenyl]piperazine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1OCCCN1CCCC1 HMKHZGQQZUYGOX-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- JRGGUPZKKTVKOV-UHFFFAOYSA-N 1-bromo-3-chlorobenzene Chemical compound ClC1=CC=CC(Br)=C1 JRGGUPZKKTVKOV-UHFFFAOYSA-N 0.000 description 1
- DKVJRZYMFJNVOD-UHFFFAOYSA-N 1-ethyl-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1N(CC)N=C2 DKVJRZYMFJNVOD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- MKTPOHXUXWUJNO-UHFFFAOYSA-N 1-tert-butyl-3-(trifluoromethyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound N1=CN=C2N(C(C)(C)C)N=C(C(F)(F)F)C2=C1O MKTPOHXUXWUJNO-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- UZURTQHPMXADGG-UHFFFAOYSA-N 2,3,3a,4,7,7a-hexahydro-1h-indene Chemical compound C1C=CCC2CCCC21 UZURTQHPMXADGG-UHFFFAOYSA-N 0.000 description 1
- PHXGAJLBHUUAKB-UHFFFAOYSA-N 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound O1CCC2OCCC21 PHXGAJLBHUUAKB-UHFFFAOYSA-N 0.000 description 1
- OZJZCCMIOZPPIT-UHFFFAOYSA-N 2-(2-methoxyethoxy)acetyl chloride Chemical compound COCCOCC(Cl)=O OZJZCCMIOZPPIT-UHFFFAOYSA-N 0.000 description 1
- GPMRZLROSLBOST-UHFFFAOYSA-N 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane;hydrochloride Chemical compound Cl.ClC1=CC=CC(N2C3CC(NC3)C2)=C1 GPMRZLROSLBOST-UHFFFAOYSA-N 0.000 description 1
- WITNOYWFEMOXJQ-UHFFFAOYSA-N 2-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC(Cl)=CC(N2CCNCC2)=C1C WITNOYWFEMOXJQ-UHFFFAOYSA-N 0.000 description 1
- NKCYQDGFDPORHX-UHFFFAOYSA-N 2-[1-hydroxy-2-(2-methoxyethoxy)ethylidene]propanedinitrile Chemical compound COCCOCC(O)=C(C#N)C#N NKCYQDGFDPORHX-UHFFFAOYSA-N 0.000 description 1
- DPBXZBAFJZFNEU-UHFFFAOYSA-N 2-[2-chloro-4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenoxy]-n,n-dimethylethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(Cl)=C(OCCN(C)C)C=C1C DPBXZBAFJZFNEU-UHFFFAOYSA-N 0.000 description 1
- KXFPRYJZNFUBAI-UHFFFAOYSA-N 2-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]-n,n-diethylethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)=C1C KXFPRYJZNFUBAI-UHFFFAOYSA-N 0.000 description 1
- ROLRVFVPEUIBKU-UHFFFAOYSA-N 2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methoxyphenoxy]-n,n-dimethylethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(Cl)=CC(OCCN(C)C)=C1OC ROLRVFVPEUIBKU-UHFFFAOYSA-N 0.000 description 1
- HRFVAWXEZPKKKI-UHFFFAOYSA-N 2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]-n,n-diethylethanamine;hydrochloride Chemical compound Cl.CCN(CC)CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C HRFVAWXEZPKKKI-UHFFFAOYSA-N 0.000 description 1
- ZSLSTFJDDMMQET-UHFFFAOYSA-N 2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]-n,n-dimethylethanamine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(OCCN(C)C)=C1C ZSLSTFJDDMMQET-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- OHQCOWQNKVFADT-UHFFFAOYSA-N 2-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1Cl)=CC(F)=CC=1NCCN1CCCC1 OHQCOWQNKVFADT-UHFFFAOYSA-N 0.000 description 1
- LMKQEPXWBDAMIA-UHFFFAOYSA-N 2-chloro-5-fluoro-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound ClC=1C(N2CCNCC2)=CC(F)=CC=1NCCN1CCCC1 LMKQEPXWBDAMIA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ZMFGJDMBUKOPBV-UHFFFAOYSA-N 2-methyl-3-piperazin-1-yl-5-propan-2-yloxy-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OC(C)C)=CC=1NCCN1CCCC1 ZMFGJDMBUKOPBV-UHFFFAOYSA-N 0.000 description 1
- BLPUNWQGIQUFNC-UHFFFAOYSA-N 2-methyl-3-piperazin-1-yl-5-propoxy-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCCC)=CC=1NCCN1CCCC1 BLPUNWQGIQUFNC-UHFFFAOYSA-N 0.000 description 1
- DFJHHZMJCJHNHH-UHFFFAOYSA-N 2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)-5-(2-trimethylsilylethyl)aniline Chemical compound C1=C(CC[Si](C)(C)C)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 DFJHHZMJCJHNHH-UHFFFAOYSA-N 0.000 description 1
- OVLBJMSFGAKMSF-UHFFFAOYSA-N 2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)-5-(3,3,3-trifluoropropoxy)aniline;hydrochloride Chemical compound Cl.C1=C(OCCC(F)(F)F)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 OVLBJMSFGAKMSF-UHFFFAOYSA-N 0.000 description 1
- DKNNPBSTUKJQAG-UHFFFAOYSA-N 2-methyl-4-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCNC(C)(C(O)=O)C1 DKNNPBSTUKJQAG-UHFFFAOYSA-N 0.000 description 1
- ZUAWCLGUHKNAIA-UHFFFAOYSA-N 2-methyl-5-(2-methylpropoxy)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCC(C)C)=CC=1NCCN1CCCC1 ZUAWCLGUHKNAIA-UHFFFAOYSA-N 0.000 description 1
- ZYKQWDMKJZVYIU-UHFFFAOYSA-N 2-methyl-5-(2-phenylethyl)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(CCC=2C=CC=CC=2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 ZYKQWDMKJZVYIU-UHFFFAOYSA-N 0.000 description 1
- OVJNRSLJOAJKEE-UHFFFAOYSA-N 2-methyl-5-(2-phenylethynyl)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(C#CC=2C=CC=CC=2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 OVJNRSLJOAJKEE-UHFFFAOYSA-N 0.000 description 1
- JZGASZBCHPZJHD-UHFFFAOYSA-N 2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC1=NOC(C=2C=C(C(C)=C(NCCN3CCCC3)C=2)N2CCNCC2)=N1 JZGASZBCHPZJHD-UHFFFAOYSA-N 0.000 description 1
- BDWVGFUBSJWIHS-UHFFFAOYSA-N 2-methyl-5-(3-methylbutoxy)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCCC(C)C)=CC=1NCCN1CCCC1 BDWVGFUBSJWIHS-UHFFFAOYSA-N 0.000 description 1
- CVVNTEJYPAXKCF-UHFFFAOYSA-N 2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(C=2ON=C(N=2)C=2C=CC=CC=2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 CVVNTEJYPAXKCF-UHFFFAOYSA-N 0.000 description 1
- XAFANKYUWHODAK-UHFFFAOYSA-N 2-methyl-5-(oxolan-2-ylmethoxy)-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2OCCC2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 XAFANKYUWHODAK-UHFFFAOYSA-N 0.000 description 1
- KKTJBKMAHMUXSN-UHFFFAOYSA-N 2-methyl-5-methylsulfonyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(S(C)(=O)=O)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 KKTJBKMAHMUXSN-UHFFFAOYSA-N 0.000 description 1
- SGNVAYIPRSEKFH-UHFFFAOYSA-N 2-methyl-5-phenylmethoxy-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC=2C=CC=CC=2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 SGNVAYIPRSEKFH-UHFFFAOYSA-N 0.000 description 1
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical group CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CGNJNFZTDWGNSF-UHFFFAOYSA-N 2h-pyrimidin-1-amine Chemical compound NN1CN=CC=C1 CGNJNFZTDWGNSF-UHFFFAOYSA-N 0.000 description 1
- PPWNCLVNXGCGAF-UHFFFAOYSA-N 3,3-dimethylbut-1-yne Chemical compound CC(C)(C)C#C PPWNCLVNXGCGAF-UHFFFAOYSA-N 0.000 description 1
- HUWLDUMHTSHONZ-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(C=4C=C5OCOC5=CC=4)NN=C3N=CN=2)CC1 HUWLDUMHTSHONZ-UHFFFAOYSA-N 0.000 description 1
- GAUUCHYDLVWVTQ-UHFFFAOYSA-N 3-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCOC1=CC(Cl)=CC(N2CCNCC2)=C1C GAUUCHYDLVWVTQ-UHFFFAOYSA-N 0.000 description 1
- RGGPCUABEGXGQB-UHFFFAOYSA-N 3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(C=C4CNC4)NN=C3N=CN=2)CC1 RGGPCUABEGXGQB-UHFFFAOYSA-N 0.000 description 1
- KKGUMGWNFARLSL-UHFFFAOYSA-N 3-(bromomethyl)pentane Chemical compound CCC(CC)CBr KKGUMGWNFARLSL-UHFFFAOYSA-N 0.000 description 1
- RZAHIWXBDWFJID-UHFFFAOYSA-N 3-[2-chloro-4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenoxy]-n,n-dimethylpropan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(Cl)=C(OCCCN(C)C)C=C1C RZAHIWXBDWFJID-UHFFFAOYSA-N 0.000 description 1
- UXCHHUGMTOICBK-UHFFFAOYSA-N 3-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenoxy]-n,n-diethylpropan-1-amine;hydrochloride Chemical compound Cl.CCN(CC)CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C UXCHHUGMTOICBK-UHFFFAOYSA-N 0.000 description 1
- REMJBFLHUDUAAB-UHFFFAOYSA-N 3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-(2-trimethylsilylethyl)aniline 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(CC[Si](C)(C)C)C=C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)C(C)=C1NCCN1CCCC1 REMJBFLHUDUAAB-UHFFFAOYSA-N 0.000 description 1
- DXRQWKMABDCEPQ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-fluoro-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.ClC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(F)=CC=1NCCN1CCCC1 DXRQWKMABDCEPQ-UHFFFAOYSA-N 0.000 description 1
- HNXHTZJWDDEAPU-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methylbutoxy)-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCCC(C)C)=CC=1NCCN1CCCC1 HNXHTZJWDDEAPU-UHFFFAOYSA-N 0.000 description 1
- PGVQMDPVMHGBQK-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(C=2ON=C(N=2)C=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 PGVQMDPVMHGBQK-UHFFFAOYSA-N 0.000 description 1
- WBOUCZBCMVVFCT-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-propan-2-yloxy-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OC(C)C)=CC=1NCCN1CCCC1 WBOUCZBCMVVFCT-UHFFFAOYSA-N 0.000 description 1
- OQKYBAPVQVRKNQ-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-methoxyethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCCOC)=CC=1NCCN1CCCC1 OQKYBAPVQVRKNQ-UHFFFAOYSA-N 0.000 description 1
- SHPKPYILMUKFEL-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(cyclohexylmethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2CCCCC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 SHPKPYILMUKFEL-UHFFFAOYSA-N 0.000 description 1
- IXVIFKUANGTJCC-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(cyclopropylmethoxy)-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2CC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 IXVIFKUANGTJCC-UHFFFAOYSA-N 0.000 description 1
- OVASKJWVAVYOBN-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethoxy-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(OCC)=CC=1NCCN1CCCC1 OVASKJWVAVYOBN-UHFFFAOYSA-N 0.000 description 1
- OPOIVVNFQFPRCR-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethyl-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC=1C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)=CC(CC)=CC=1NCCN1CCCC1 OPOIVVNFQFPRCR-UHFFFAOYSA-N 0.000 description 1
- HMOJRYPCFXCCOD-UHFFFAOYSA-N 3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethynyl-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C#C)C=C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)C(C)=C1NCCN1CCCC1 HMOJRYPCFXCCOD-UHFFFAOYSA-N 0.000 description 1
- MMEGZVSPBZFNNO-UHFFFAOYSA-N 3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)-n-(2-pyrrolidin-1-ylethyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(OCC(C)C)=CC=1NCCN1CCCC1 MMEGZVSPBZFNNO-UHFFFAOYSA-N 0.000 description 1
- VAVUERYYXDBTAO-UHFFFAOYSA-N 3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-phenylmethoxy-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C(=C(NCCN1CCCC1)C=1)C)=CC=1OCC1=CC=CC=C1 VAVUERYYXDBTAO-UHFFFAOYSA-N 0.000 description 1
- RUQUXSJOPZLPKC-UHFFFAOYSA-N 3-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-5-(2-pyrrolidin-1-ylethylamino)benzoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC(NCCN2CCCC2)=CC(C(O)=O)=C1 RUQUXSJOPZLPKC-UHFFFAOYSA-N 0.000 description 1
- YMLMLJNFVOKXBP-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C#CCO)=NN(C=3N=CN=2)C2OCCCC2)CC1 YMLMLJNFVOKXBP-UHFFFAOYSA-N 0.000 description 1
- WMIMZCRRUJOOLF-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]-n,n-diethylpropan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CCCN(CC)CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(Cl)=CC=C1C WMIMZCRRUJOOLF-UHFFFAOYSA-N 0.000 description 1
- JJOUSWZGGIWTQV-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]aniline;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(N)C=CC=4)=NNC=3N=CN=2)CC1 JJOUSWZGGIWTQV-UHFFFAOYSA-N 0.000 description 1
- KUXRYMPTTGNOEI-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(C=CC=4)C(O)=O)=NNC=3N=CN=2)CC1 KUXRYMPTTGNOEI-UHFFFAOYSA-N 0.000 description 1
- HNWRGXBWEZEZMH-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]phenol;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(O)C=CC=4)=NNC=3N=CN=2)CC1 HNWRGXBWEZEZMH-UHFFFAOYSA-N 0.000 description 1
- HKEJFUHECWPQKD-UHFFFAOYSA-N 3-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]-n,n-diethylpropan-1-amine;hydrochloride Chemical compound Cl.CCN(CC)CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C HKEJFUHECWPQKD-UHFFFAOYSA-N 0.000 description 1
- FJHDRIZZFXDPIZ-UHFFFAOYSA-N 3-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenyl]-n,n-diethylpropan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCN(CC)CCCC1=CC(Cl)=CC(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)=C1C FJHDRIZZFXDPIZ-UHFFFAOYSA-N 0.000 description 1
- QUEZQNSZWRZLCB-UHFFFAOYSA-N 3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]-n,n-diethylpropan-1-amine;hydrochloride Chemical compound Cl.CCN(CC)CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C QUEZQNSZWRZLCB-UHFFFAOYSA-N 0.000 description 1
- LVAYWLZOLMFGOM-UHFFFAOYSA-N 3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n,n-diethylpropan-1-amine;hydrochloride Chemical compound Cl.CCN(CC)CCCC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C LVAYWLZOLMFGOM-UHFFFAOYSA-N 0.000 description 1
- RAXMUHNCMQAQSH-UHFFFAOYSA-N 3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n,n-dimethylprop-2-yn-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(Cl)=CC(C#CCN(C)C)=C1C RAXMUHNCMQAQSH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YSEOWINAKUGZSZ-UHFFFAOYSA-N 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidine Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(Br)=NN(C=3N=CN=2)C2OCCCC2)CC1 YSEOWINAKUGZSZ-UHFFFAOYSA-N 0.000 description 1
- CSXVQPBQDYAKDK-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(C)CCC1COC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C CSXVQPBQDYAKDK-UHFFFAOYSA-N 0.000 description 1
- HIWHRYZBEQXNCL-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[2-(1-methylpiperidin-4-yl)ethoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(C)CCC1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C HIWHRYZBEQXNCL-UHFFFAOYSA-N 0.000 description 1
- TYKANOSYGXUPIU-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(C)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C TYKANOSYGXUPIU-UHFFFAOYSA-N 0.000 description 1
- LTPIFSNYAGAFQP-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(C)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C LTPIFSNYAGAFQP-UHFFFAOYSA-N 0.000 description 1
- FGJFTFJHSPZCLV-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-3-[2-(4-ethylpiperazin-1-yl)ethoxy]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C FGJFTFJHSPZCLV-UHFFFAOYSA-N 0.000 description 1
- AFRSPPDYILFHIW-UHFFFAOYSA-N 3-bromo-4-[4-[5-chloro-3-[3-(4-ethylpiperazin-1-yl)propoxy]-2-methylphenyl]piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C AFRSPPDYILFHIW-UHFFFAOYSA-N 0.000 description 1
- DVECOUBXTSYIFO-UHFFFAOYSA-N 3-bromo-5-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-n-phenylbenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C(=C(Br)C=1)C)=CC=1C(=O)NC1=CC=CC=C1 DVECOUBXTSYIFO-UHFFFAOYSA-N 0.000 description 1
- KCPLJPHQKPGNHT-UHFFFAOYSA-N 3-phenyl-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=2C(O)=NC=NC=2NN=C1C1=CC=CC=C1 KCPLJPHQKPGNHT-UHFFFAOYSA-N 0.000 description 1
- ALUSQWKDVGPZPB-UHFFFAOYSA-N 4,4,4-trifluoro-1-[4-methyl-3-piperazin-1-yl-5-(2-pyrrolidin-1-ylethylamino)phenyl]butan-1-one;hydrochloride Chemical compound Cl.C1=C(C(=O)CCC(F)(F)F)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 ALUSQWKDVGPZPB-UHFFFAOYSA-N 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- IYWKLFKURTWJFJ-UHFFFAOYSA-N 4-(3-chlorophenyl)-n-methylpiperazine-2-carboxamide Chemical compound C1CNC(C(=O)NC)CN1C1=CC=CC(Cl)=C1 IYWKLFKURTWJFJ-UHFFFAOYSA-N 0.000 description 1
- GMUPYKQZMBLHEB-UHFFFAOYSA-N 4-(4-phenylpiperidin-1-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CCC1C1=CC=CC=C1 GMUPYKQZMBLHEB-UHFFFAOYSA-N 0.000 description 1
- RBIGGFXRTIGRON-UHFFFAOYSA-N 4-[2-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)ethyl]morpholine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1OCCN1CCOCC1 RBIGGFXRTIGRON-UHFFFAOYSA-N 0.000 description 1
- JTMHRIMHYBXMQR-UHFFFAOYSA-N 4-[2-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]ethyl]morpholine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)C(C)=C1OCCN1CCOCC1 JTMHRIMHYBXMQR-UHFFFAOYSA-N 0.000 description 1
- CILVJYXWYQSTCB-UHFFFAOYSA-N 4-[2-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenoxy]ethyl]morpholine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCOCC1 CILVJYXWYQSTCB-UHFFFAOYSA-N 0.000 description 1
- VYHIONPWWCKWOF-UHFFFAOYSA-N 4-[3-(5-chloro-2-methyl-3-piperazin-1-ylphenoxy)propyl]morpholine Chemical compound C1=C(Cl)C=C(N2CCNCC2)C(C)=C1OCCCN1CCOCC1 VYHIONPWWCKWOF-UHFFFAOYSA-N 0.000 description 1
- CCVDVJXNLXZBAN-UHFFFAOYSA-N 4-[3-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenoxy]propyl]morpholine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)C(C)=C1OCCCN1CCOCC1 CCVDVJXNLXZBAN-UHFFFAOYSA-N 0.000 description 1
- POEJPYMKOSSIGK-UHFFFAOYSA-N 4-[3-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]propyl]morpholine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1CCCN1CCOCC1 POEJPYMKOSSIGK-UHFFFAOYSA-N 0.000 description 1
- GPCOCFSLOGRFHR-UHFFFAOYSA-N 4-[3-bromo-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]piperazine-1-carboxylic acid Chemical compound CC1=C(Br)C=C(C=2ON=C(N=2)C=2C=CC=CC=2)C=C1N1CCN(C(O)=O)CC1 GPCOCFSLOGRFHR-UHFFFAOYSA-N 0.000 description 1
- YRKKQVKSWQLXBZ-UHFFFAOYSA-N 4-[4-(2-chlorophenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=CC=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 YRKKQVKSWQLXBZ-UHFFFAOYSA-N 0.000 description 1
- IBXALBYOWBTGRR-UHFFFAOYSA-N 4-[4-(2-fluorophenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound FC1=CC=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 IBXALBYOWBTGRR-UHFFFAOYSA-N 0.000 description 1
- PNKDJCFGTHLQCJ-UHFFFAOYSA-N 4-[4-(2-methoxyphenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 PNKDJCFGTHLQCJ-UHFFFAOYSA-N 0.000 description 1
- CTJVUQNXXFJPAN-UHFFFAOYSA-N 4-[4-(2-methylphenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 CTJVUQNXXFJPAN-UHFFFAOYSA-N 0.000 description 1
- ZIYLOLUWFBWXIH-UHFFFAOYSA-N 4-[4-(3-chlorophenyl)-1,4-diazepan-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C=12C(CC)=NNC2=NC=NC=1N(CC1)CCCN1C1=CC=CC(Cl)=C1 ZIYLOLUWFBWXIH-UHFFFAOYSA-N 0.000 description 1
- WUWSJZJZLJLZJJ-UHFFFAOYSA-N 4-[4-(3-chlorophenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=CC=CC(N2CCN(CC2)C=2C=3C=CNC=3N=CN=2)=C1 WUWSJZJZLJLZJJ-UHFFFAOYSA-N 0.000 description 1
- YCDVPZJRYIIRMM-UHFFFAOYSA-N 4-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6,7-dimethoxyquinazoline;hydrochloride Chemical compound Cl.COC1=C(OC)C=C2C(N3CCN(CC3)C=3N=CN=C4NN=C(C=34)CC)=NC=NC2=C1 YCDVPZJRYIIRMM-UHFFFAOYSA-N 0.000 description 1
- FWECWZKFGBIJMK-UHFFFAOYSA-N 4-[4-(3-methoxyphenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=CC(N2CCN(CC2)C=2C=3C=CNC=3N=CN=2)=C1 FWECWZKFGBIJMK-UHFFFAOYSA-N 0.000 description 1
- BKUPEAMZZKHYFG-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(Cl)=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 BKUPEAMZZKHYFG-UHFFFAOYSA-N 0.000 description 1
- MGAUNJWDDNBFEB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(F)=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 MGAUNJWDDNBFEB-UHFFFAOYSA-N 0.000 description 1
- AAICARCSHFYCBL-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=3C=CNC=3N=CN=2)CC1 AAICARCSHFYCBL-UHFFFAOYSA-N 0.000 description 1
- ACZXBVMTGYCNEN-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.COC1=CC=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 ACZXBVMTGYCNEN-UHFFFAOYSA-N 0.000 description 1
- ALWXPUXBRVQMDL-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-chloropyridin-4-yl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(C=4C(=CN=CC=4)Cl)NN=C3N=CN=2)CC1 ALWXPUXBRVQMDL-UHFFFAOYSA-N 0.000 description 1
- ADJZJDJUQKXOMS-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-fluoropyridin-4-yl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(C=4C(=CN=CC=4)F)NN=C3N=CN=2)CC1 ADJZJDJUQKXOMS-UHFFFAOYSA-N 0.000 description 1
- OMCCPHMUSBKOEW-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C2=C3C(N4CCN(CC4)C=4C(=CC=C(Cl)C=4)C)=NC=NC3=NN2)=C1 OMCCPHMUSBKOEW-UHFFFAOYSA-N 0.000 description 1
- RDZNVJSIJFRQLN-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-enyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C=12C(CC=C(C)C)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC=C1C RDZNVJSIJFRQLN-UHFFFAOYSA-N 0.000 description 1
- CFGPESOSYCRXJM-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-phenylmethoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=C(OCC=5C=CC=CC=5)C=CC=4)=NNC=3N=CN=2)CC1 CFGPESOSYCRXJM-UHFFFAOYSA-N 0.000 description 1
- ADBQQNVNDJBSPR-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylpropyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(CCCN4CCCC4)NN=C3N=CN=2)CC1 ADBQQNVNDJBSPR-UHFFFAOYSA-N 0.000 description 1
- WUGZCLZJRNBWGH-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-fluorophenyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(F)=CC=4)=NNC=3N=CN=2)CC1 WUGZCLZJRNBWGH-UHFFFAOYSA-N 0.000 description 1
- MZFQSBSBOCXURY-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 MZFQSBSBOCXURY-UHFFFAOYSA-N 0.000 description 1
- PYAXKDBTDYPILG-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylphenyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 PYAXKDBTDYPILG-UHFFFAOYSA-N 0.000 description 1
- PSQXKUZZVBIEGS-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-phenoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(OC=5C=CC=CC=5)=CC=4)=NNC=3N=CN=2)CC1 PSQXKUZZVBIEGS-UHFFFAOYSA-N 0.000 description 1
- LCTJNACRHLPHCC-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(piperidin-4-ylmethyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C3=C(CC4CCNCC4)NN=C3N=CN=2)CC1 LCTJNACRHLPHCC-UHFFFAOYSA-N 0.000 description 1
- JPIRECAMUSZVHI-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(piperidin-4-ylmethoxy)phenyl]-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(OCC5CCNCC5)=CC=4)=NNC=3N=CN=2)CC1 JPIRECAMUSZVHI-UHFFFAOYSA-N 0.000 description 1
- LJTNPOMRKDRDDX-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-pyridin-4-yl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CN=CC=4)=NNC=3N=CN=2)CC1 LJTNPOMRKDRDDX-UHFFFAOYSA-N 0.000 description 1
- JAQCOIIUEBIFCE-UHFFFAOYSA-N 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-thiophen-2-yl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4SC=CC=4)=NNC=3N=CN=2)CC1 JAQCOIIUEBIFCE-UHFFFAOYSA-N 0.000 description 1
- HRFDNZHBOSXNJX-UHFFFAOYSA-N 4-[4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(C(F)(F)F)=CC=C1Cl HRFDNZHBOSXNJX-UHFFFAOYSA-N 0.000 description 1
- YISGVHBBSBDPLQ-UHFFFAOYSA-N 4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC2)C=2C=3C=CNC=3N=CN=2)=C1 YISGVHBBSBDPLQ-UHFFFAOYSA-N 0.000 description 1
- ADNQTKKLFYIXOD-UHFFFAOYSA-N 4-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C=4C=CC(=CC=4)C#N)=NNC=3N=CN=2)CC1 ADNQTKKLFYIXOD-UHFFFAOYSA-N 0.000 description 1
- HQEDABRUWZCNLW-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1OCCN1CCCCC1 HQEDABRUWZCNLW-UHFFFAOYSA-N 0.000 description 1
- VKQQVRILEOLGGH-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCCC1 VKQQVRILEOLGGH-UHFFFAOYSA-N 0.000 description 1
- CFUYCXAVBBYTOY-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-(2-methylpropyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC(C)C)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 CFUYCXAVBBYTOY-UHFFFAOYSA-N 0.000 description 1
- VUYPARZAFPXXRA-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)C(C)=C1OCCN1CCCC1 VUYPARZAFPXXRA-UHFFFAOYSA-N 0.000 description 1
- BKVWBBPEOOUCSR-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 BKVWBBPEOOUCSR-UHFFFAOYSA-N 0.000 description 1
- GUUIFYHFFRHFBZ-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)phenyl]piperazin-1-yl]-3-propan-2-yl-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(C(C)C)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCCC1 GUUIFYHFFRHFBZ-UHFFFAOYSA-N 0.000 description 1
- XGYIRABXHUEQMY-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)C(C)=C1OCCCN1CCCCC1 XGYIRABXHUEQMY-UHFFFAOYSA-N 0.000 description 1
- OIWSVSQGOROZBB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)C(C)=C1CCCN1CCCCC1 OIWSVSQGOROZBB-UHFFFAOYSA-N 0.000 description 1
- QEGYOIPCNDGRJA-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1CCCN1CCCCC1 QEGYOIPCNDGRJA-UHFFFAOYSA-N 0.000 description 1
- FAGYIQZPQWAMIH-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropoxy)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(NN=C3N=CN=2)C(F)(F)F)C(C)=C1OCCCN1CCCC1 FAGYIQZPQWAMIH-UHFFFAOYSA-N 0.000 description 1
- FWMXCFUMSBFAAI-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=C(Cl)C=C(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)C(C)=C1CCCN1CCCC1 FWMXCFUMSBFAAI-UHFFFAOYSA-N 0.000 description 1
- UMAHJFYRLZKLOT-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1CCCN1CCCC1 UMAHJFYRLZKLOT-UHFFFAOYSA-N 0.000 description 1
- HFXWHWGFDJBVQH-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(C)CCC1COC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C HFXWHWGFDJBVQH-UHFFFAOYSA-N 0.000 description 1
- MNSFYCKQACUVJB-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCC1CCN(C)CC1 MNSFYCKQACUVJB-UHFFFAOYSA-N 0.000 description 1
- JOIVONGZLVWEHI-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(1-methylpiperidin-4-yl)ethoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCC1CCN(C)CC1 JOIVONGZLVWEHI-UHFFFAOYSA-N 0.000 description 1
- JYWUNYPUTQRCHE-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(C)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C JYWUNYPUTQRCHE-UHFFFAOYSA-N 0.000 description 1
- IPFGHGNLNCWHKN-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCN1CCN(C)CC1 IPFGHGNLNCWHKN-UHFFFAOYSA-N 0.000 description 1
- HBRFNDKRWBFTPH-UHFFFAOYSA-N 4-[4-[5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1OCCCN1CCN(C)CC1 HBRFNDKRWBFTPH-UHFFFAOYSA-N 0.000 description 1
- UPZLGMPAYVCPFC-UHFFFAOYSA-N 4-[4-[5-chloro-3-[2-(4-ethylpiperazin-1-yl)ethoxy]-2-methylphenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C UPZLGMPAYVCPFC-UHFFFAOYSA-N 0.000 description 1
- XKNJFTICVUXZNU-UHFFFAOYSA-N 4-[4-[5-chloro-3-[2-(4-ethylpiperazin-1-yl)ethoxy]-2-methylphenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(CC)CCN1CCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C XKNJFTICVUXZNU-UHFFFAOYSA-N 0.000 description 1
- APEXOLLBPUHHJU-UHFFFAOYSA-N 4-[4-[5-chloro-3-[3-(4-ethylpiperazin-1-yl)propoxy]-2-methylphenyl]piperazin-1-yl]-3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C APEXOLLBPUHHJU-UHFFFAOYSA-N 0.000 description 1
- AWFYCBLBBLZBBT-UHFFFAOYSA-N 4-[4-[5-chloro-3-[3-(4-ethylpiperazin-1-yl)propoxy]-2-methylphenyl]piperazin-1-yl]-3-ethyl-2h-pyrazolo[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1CN(CC)CCN1CCCOC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(CC)=NNC=3N=CN=2)=C1C AWFYCBLBBLZBBT-UHFFFAOYSA-N 0.000 description 1
- OUWGWVYCIKZPJZ-UHFFFAOYSA-N 4-[5-(2-ethylbutoxy)-2-methyl-3-(2-pyrrolidin-1-ylethylamino)phenyl]piperazine-1-carboxylic acid Chemical compound CCC(CC)COC1=CC(=C(C(=C1)N2CCN(CC2)C(=O)O)C)NCCN3CCCC3 OUWGWVYCIKZPJZ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VIBJPUXLAKVICD-UHFFFAOYSA-N 4-bromo-2-chlorophenol Chemical compound OC1=CC=C(Br)C=C1Cl VIBJPUXLAKVICD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- CVFQKJBAFPUOOE-UHFFFAOYSA-N 4-methyl-3-[2-pyrrolidin-1-ylethyl-(2,2,2-trifluoroacetyl)amino]-5-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]benzoic acid Chemical compound CC1=C(N(CCN2CCCC2)C(=O)C(F)(F)F)C=C(C(O)=O)C=C1N1CCN(C(=O)C(F)(F)F)CC1 CVFQKJBAFPUOOE-UHFFFAOYSA-N 0.000 description 1
- PBIOBGXIHSGZEZ-UHFFFAOYSA-N 4-methyl-3-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-5-(2-pyrrolidin-1-ylethylamino)benzoic acid Chemical compound C1=C(C(O)=O)C=C(N2CCN(CC2)C(=O)OC(C)(C)C)C(C)=C1NCCN1CCCC1 PBIOBGXIHSGZEZ-UHFFFAOYSA-N 0.000 description 1
- UPIPEVYDDHOZJJ-UHFFFAOYSA-N 5-(2,2-dimethylpropoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC(C)(C)C)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 UPIPEVYDDHOZJJ-UHFFFAOYSA-N 0.000 description 1
- KJGKXCRDIOPBQR-UHFFFAOYSA-N 5-(2-ethylbutoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCC(CC)CC)=CC=1NCCN1CCCC1 KJGKXCRDIOPBQR-UHFFFAOYSA-N 0.000 description 1
- YCMKEWPJERHVGV-UHFFFAOYSA-N 5-(2-methoxyethoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCCOC)=CC=1NCCN1CCCC1 YCMKEWPJERHVGV-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- RJRXXFWGGQCTAJ-UHFFFAOYSA-N 5-(cyclobutylmethoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2CCC2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 RJRXXFWGGQCTAJ-UHFFFAOYSA-N 0.000 description 1
- HTZKMBJOSMXQBG-UHFFFAOYSA-N 5-(cyclohexylmethoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2CCCCC2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 HTZKMBJOSMXQBG-UHFFFAOYSA-N 0.000 description 1
- HBWVVLFIYSFTDP-UHFFFAOYSA-N 5-(cyclopentylmethoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(OCC2CCCC2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 HBWVVLFIYSFTDP-UHFFFAOYSA-N 0.000 description 1
- GEMJHKMQCUNCOZ-UHFFFAOYSA-N 5-(cyclopropylmethoxy)-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2CC2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 GEMJHKMQCUNCOZ-UHFFFAOYSA-N 0.000 description 1
- MTEKHXNKEDKMHO-UHFFFAOYSA-N 5-[(2,2-difluorocyclopropyl)methoxy]-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(OCC2C(C2)(F)F)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 MTEKHXNKEDKMHO-UHFFFAOYSA-N 0.000 description 1
- VHYFWRJMROZALU-UHFFFAOYSA-N 5-bromo-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(Br)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 VHYFWRJMROZALU-UHFFFAOYSA-N 0.000 description 1
- FKAJOXHDKWTYQZ-UHFFFAOYSA-N 5-butoxy-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCCCC)=CC=1NCCN1CCCC1 FKAJOXHDKWTYQZ-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- MYVSNTMBLBJVAR-UHFFFAOYSA-N 5-chloro-2-methoxy-3-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]benzoic acid Chemical compound C1=C(Cl)C=C(C(O)=O)C(OC)=C1N1CCN(C(=O)OC(C)(C)C)CC1 MYVSNTMBLBJVAR-UHFFFAOYSA-N 0.000 description 1
- ANFXMRFYWDHHHT-UHFFFAOYSA-N 5-chloro-2-methyl-3-[4-(3-propan-2-yl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(C(C)C)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1NCCN1CCCC1 ANFXMRFYWDHHHT-UHFFFAOYSA-N 0.000 description 1
- WOLNFTWSDNSDEN-UHFFFAOYSA-N 5-chloro-2-methyl-3-[4-[3-(2-methylpropyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC(C)C)NN=C2N=CN=C1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1NCCN1CCCC1 WOLNFTWSDNSDEN-UHFFFAOYSA-N 0.000 description 1
- WUJBPUKAUVTGRW-UHFFFAOYSA-N 5-chloro-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C1=C(Cl)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 WUJBPUKAUVTGRW-UHFFFAOYSA-N 0.000 description 1
- NUCGEMSYYFGJRC-UHFFFAOYSA-N 5-chloro-3-[4-(3-cyclopropyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C=C(N2CCN(CC2)C=2C3=C(C4CC4)NN=C3N=CN=2)C(C)=C1NCCN1CCCC1 NUCGEMSYYFGJRC-UHFFFAOYSA-N 0.000 description 1
- QCXASTMRNOVYOP-UHFFFAOYSA-N 5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C(C=1C)=CC(Cl)=CC=1NCCN1CCCC1 QCXASTMRNOVYOP-UHFFFAOYSA-N 0.000 description 1
- SQYMZORQAUTURP-UHFFFAOYSA-N 5-ethoxy-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(OCC)=CC=1NCCN1CCCC1 SQYMZORQAUTURP-UHFFFAOYSA-N 0.000 description 1
- JPGPPHISZFDACG-UHFFFAOYSA-N 5-ethyl-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC=1C(N2CCNCC2)=CC(CC)=CC=1NCCN1CCCC1 JPGPPHISZFDACG-UHFFFAOYSA-N 0.000 description 1
- HCTCMHHQMDCVGD-UHFFFAOYSA-N 5-ethylsulfonyl-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline;hydrochloride Chemical compound Cl.CC=1C(N2CCNCC2)=CC(S(=O)(=O)CC)=CC=1NCCN1CCCC1 HCTCMHHQMDCVGD-UHFFFAOYSA-N 0.000 description 1
- RJMAPNOOJUQGCI-UHFFFAOYSA-N 5-ethynyl-2-methyl-3-piperazin-1-yl-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(C#C)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 RJMAPNOOJUQGCI-UHFFFAOYSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- MWRLTPXFGZXUKB-UHFFFAOYSA-N 6-[4-(2-methylphenyl)piperazin-1-yl]-7h-purine Chemical compound CC1=CC=CC=C1N1CCN(C=2C=3N=CNC=3N=CN=2)CC1 MWRLTPXFGZXUKB-UHFFFAOYSA-N 0.000 description 1
- IQFNNPBWPNNACU-UHFFFAOYSA-N 6-[4-(4-chlorophenyl)piperazin-1-yl]-7h-purine Chemical compound C1=CC(Cl)=CC=C1N1CCN(C=2C=3N=CNC=3N=CN=2)CC1 IQFNNPBWPNNACU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000007299 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102400001242 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- LZTAFOFVUWLZLV-UHFFFAOYSA-N C(O)CN.CN(C)C Chemical compound C(O)CN.CN(C)C LZTAFOFVUWLZLV-UHFFFAOYSA-N 0.000 description 1
- NLTYMRXEVHKXQJ-UHFFFAOYSA-N C1=NN(C2=C1C(=NC=N2)Cl)Br Chemical compound C1=NN(C2=C1C(=NC=N2)Cl)Br NLTYMRXEVHKXQJ-UHFFFAOYSA-N 0.000 description 1
- HIHDQUDZEYDANU-UHFFFAOYSA-N C1CN(CCC1C2=CC=CC=C2)C3=NC=NC4=C3C=NN4 Chemical compound C1CN(CCC1C2=CC=CC=C2)C3=NC=NC4=C3C=NN4 HIHDQUDZEYDANU-UHFFFAOYSA-N 0.000 description 1
- FBRXHYNGRXFQLH-UHFFFAOYSA-N CC(CCC#CC1=CC=CC=C1)C2=CC3=CC=CC=C3C=C2 Chemical compound CC(CCC#CC1=CC=CC=C1)C2=CC3=CC=CC=C3C=C2 FBRXHYNGRXFQLH-UHFFFAOYSA-N 0.000 description 1
- YTCHPCFFGGHTIH-UHFFFAOYSA-N CC1=C(C=C(C=C1N(CCN2CCCC2)C(=O)C(F)(F)F)OC(=O)N)N3CCN(CC3)C(=O)C(F)(F)F Chemical compound CC1=C(C=C(C=C1N(CCN2CCCC2)C(=O)C(F)(F)F)OC(=O)N)N3CCN(CC3)C(=O)C(F)(F)F YTCHPCFFGGHTIH-UHFFFAOYSA-N 0.000 description 1
- FOKLBIQRIMWIBL-UHFFFAOYSA-N CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)C(=O)N(C)OC)NCCN3CCCC3 Chemical compound CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)C(=O)N(C)OC)NCCN3CCCC3 FOKLBIQRIMWIBL-UHFFFAOYSA-N 0.000 description 1
- WCMVKPQWWVOFJU-UHFFFAOYSA-N CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)CCC(C)(C)C)NCCN3CCCC3 Chemical compound CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)CCC(C)(C)C)NCCN3CCCC3 WCMVKPQWWVOFJU-UHFFFAOYSA-N 0.000 description 1
- MQDNXMKFOBGNPE-UHFFFAOYSA-N CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)Cl)NCCN(C)C Chemical compound CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)Cl)NCCN(C)C MQDNXMKFOBGNPE-UHFFFAOYSA-N 0.000 description 1
- CWFRZJSUDFCKNL-UHFFFAOYSA-N CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)OS(=O)(=O)C(F)(F)F)NCCN3CCCC3 Chemical compound CC1=C(C=C(C=C1N2CCN(CC2)C(=O)O)OS(=O)(=O)C(F)(F)F)NCCN3CCCC3 CWFRZJSUDFCKNL-UHFFFAOYSA-N 0.000 description 1
- GOTZFIBGBBDDJY-UHFFFAOYSA-N CC1=C(I)C=C(Cl)C=C1N1CCN(C(O)=O)CC1 Chemical compound CC1=C(I)C=C(Cl)C=C1N1CCN(C(O)=O)CC1 GOTZFIBGBBDDJY-UHFFFAOYSA-N 0.000 description 1
- AYTGGFYAQLGIAP-UHFFFAOYSA-N CCC1=C2C(=NN1)N=CN=C2N3CCN(CC3)C4=CC(=CC(=C4OC)C(=O)O)Cl Chemical compound CCC1=C2C(=NN1)N=CN=C2N3CCN(CC3)C4=CC(=CC(=C4OC)C(=O)O)Cl AYTGGFYAQLGIAP-UHFFFAOYSA-N 0.000 description 1
- ASBYUYDCVPGWJR-UHFFFAOYSA-N CCN(CC)C(C)OC1=CC(=CC(=C1C)N2CCNCC2)Cl Chemical compound CCN(CC)C(C)OC1=CC(=CC(=C1C)N2CCNCC2)Cl ASBYUYDCVPGWJR-UHFFFAOYSA-N 0.000 description 1
- 102000038625 CMGCs Human genes 0.000 description 1
- 108091007913 CMGCs Proteins 0.000 description 1
- LUYKTXSJCPPLHD-UHFFFAOYSA-N CN(C(=O)C1=CC(=CC(=C1)N2CCN(CC2)C(=O)O)NCCN3CCCC3)OC Chemical compound CN(C(=O)C1=CC(=CC(=C1)N2CCN(CC2)C(=O)O)NCCN3CCCC3)OC LUYKTXSJCPPLHD-UHFFFAOYSA-N 0.000 description 1
- YSXPUAUXTOXTGT-UHFFFAOYSA-N CN(C(=O)C1=CC(=CC(=C1)N2CCNCC2)NCCN3CCCC3)OC Chemical compound CN(C(=O)C1=CC(=CC(=C1)N2CCNCC2)NCCN3CCCC3)OC YSXPUAUXTOXTGT-UHFFFAOYSA-N 0.000 description 1
- JOKBTBYKTFJMTE-UHFFFAOYSA-N CN(C)CCNC(=O)C1=C(C(=CC(=C1)Cl)N2CCNCC2)OC Chemical compound CN(C)CCNC(=O)C1=C(C(=CC(=C1)Cl)N2CCNCC2)OC JOKBTBYKTFJMTE-UHFFFAOYSA-N 0.000 description 1
- BDQHKOFICQVUPE-UHFFFAOYSA-N COC(=O)C1=CC(=CC(=C1)N2CCN(CC2)C(=O)O)NCCN3CCCC3 Chemical compound COC(=O)C1=CC(=CC(=C1)N2CCN(CC2)C(=O)O)NCCN3CCCC3 BDQHKOFICQVUPE-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101000933374 Gallus gallus Brain-specific homeobox/POU domain protein 3 Proteins 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- CGSZIBVFODKETF-UHFFFAOYSA-N NC(=O)c1c[nH]nc1N.Cc1nc(N2CCN(CC2)c2cc(Cl)ccc2C)c2cn[nH]c2n1 Chemical compound NC(=O)c1c[nH]nc1N.Cc1nc(N2CCN(CC2)c2cc(Cl)ccc2C)c2cn[nH]c2n1 CGSZIBVFODKETF-UHFFFAOYSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000590876 Steroma Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- XLRXYRAUOHNGIX-UHFFFAOYSA-N [1-(3-chlorophenyl)-4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2-yl]methanol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1CO)CCN1C1=CC=CC(Cl)=C1 XLRXYRAUOHNGIX-UHFFFAOYSA-N 0.000 description 1
- CSXVULNEGWUJTI-UHFFFAOYSA-N [1-(3-chlorophenyl)piperazin-2-yl]methanol Chemical compound OCC1CNCCN1C1=CC=CC(Cl)=C1 CSXVULNEGWUJTI-UHFFFAOYSA-N 0.000 description 1
- SBCJBPYSEVWVHA-UHFFFAOYSA-N [3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-cyclopropylmethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C(=O)C2CC2)C=C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)C(C)=C1NCCN1CCCC1 SBCJBPYSEVWVHA-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- WHQMWRNYGCEIGG-UHFFFAOYSA-N [4-methyl-3-piperazin-1-yl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-phenylmethanone;hydrochloride Chemical compound Cl.C1=C(C(=O)C=2C=CC=CC=2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 WHQMWRNYGCEIGG-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- MTZVPMQRZJBIJM-UHFFFAOYSA-N acetic acid;1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]propan-1-one Chemical compound CC(O)=O.CC=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)CC)=CC=1NCCN1CCCC1 MTZVPMQRZJBIJM-UHFFFAOYSA-N 0.000 description 1
- CBJTZQYOVHNMDH-UHFFFAOYSA-N acetic acid;1-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(2-pyrrolidin-1-ylethylamino)phenyl]butan-1-one Chemical compound CC(O)=O.C=1C(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=CC(C(=O)CCC)=CC=1NCCN1CCCC1 CBJTZQYOVHNMDH-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- MZQDCTLURFUBTB-UHFFFAOYSA-N acetic acid;3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethyl)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC(O)=O.C1=C(CCC=2C=CC=CC=2)C=C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)C(C)=C1NCCN1CCCC1 MZQDCTLURFUBTB-UHFFFAOYSA-N 0.000 description 1
- MXZXALUWZPADSD-UHFFFAOYSA-N acetic acid;3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(oxolan-2-ylmethoxy)-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC(O)=O.C1=C(OCC2OCCC2)C=C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)C(C)=C1NCCN1CCCC1 MXZXALUWZPADSD-UHFFFAOYSA-N 0.000 description 1
- DDQLGSVUJGRGMU-UHFFFAOYSA-N acetic acid;3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-propoxy-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC(O)=O.CC=1C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)=CC(OCCC)=CC=1NCCN1CCCC1 DDQLGSVUJGRGMU-UHFFFAOYSA-N 0.000 description 1
- RLRZQKOLHYZQCB-UHFFFAOYSA-N acetic acid;3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC(O)=O.C=1C(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)=CC(Cl)=CC=1NCCN1CCCC1 RLRZQKOLHYZQCB-UHFFFAOYSA-N 0.000 description 1
- MSHQLYVBLWUOPH-UHFFFAOYSA-N acetic acid;3-bromo-5-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound CC(O)=O.C12=C(Br)NN=C2N=CN=C1N(CC1)CCN1C(C=1)=CC(Br)=CC=1NCCN1CCCC1 MSHQLYVBLWUOPH-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000009949 anti-apoptotic pathway Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PJHUABJTDFXYRQ-UHFFFAOYSA-N benzoyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CC=CC=C1 PJHUABJTDFXYRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229930008407 benzylideneacetone Natural products 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- JECOSSASMXAXFV-UHFFFAOYSA-N chloroethane;hydrochloride Chemical compound Cl.CCCl JECOSSASMXAXFV-UHFFFAOYSA-N 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940061631 citric acid acetate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- VMKJWLXVLHBJNK-UHFFFAOYSA-N cyanuric fluoride Chemical compound FC1=NC(F)=NC(F)=N1 VMKJWLXVLHBJNK-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XNDLVUWJVLBZQV-UHFFFAOYSA-N cyclopropyl-[4-methyl-3-piperazin-1-yl-5-(2-pyrrolidin-1-ylethylamino)phenyl]methanone;hydrochloride Chemical compound Cl.C1=C(C(=O)C2CC2)C=C(N2CCNCC2)C(C)=C1NCCN1CCCC1 XNDLVUWJVLBZQV-UHFFFAOYSA-N 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- LWJYMKDMGMOTSB-UHFFFAOYSA-L dichlorotin;hydrate Chemical compound O.Cl[Sn]Cl LWJYMKDMGMOTSB-UHFFFAOYSA-L 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- QGBQGMHXBSLYLZ-UHFFFAOYSA-N ditert-butyl-(1-naphthalen-1-ylnaphthalen-2-yl)phosphane Chemical group C1=CC=C2C(C3=C4C=CC=CC4=CC=C3P(C(C)(C)C)C(C)(C)C)=CC=CC2=C1 QGBQGMHXBSLYLZ-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CPDKCEYBTQSMGI-UHFFFAOYSA-N ethyl 2-cyano-4,4,4-trifluoro-3-oxobutanoate Chemical compound CCOC(=O)C(C#N)C(=O)C(F)(F)F CPDKCEYBTQSMGI-UHFFFAOYSA-N 0.000 description 1
- MFDCAYVUEFZJPH-UHFFFAOYSA-N ethyl 5-amino-1-tert-butyl-3-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=C(N)N(C(C)(C)C)N=C1C(F)(F)F MFDCAYVUEFZJPH-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 108091071773 flk family Proteins 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- JZKXXXDKRQWDET-UHFFFAOYSA-N meta-tyrosine Natural products OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- ZVVXHWDADZXWBK-UHFFFAOYSA-N n'-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-n,n,n'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)C1=CC(Cl)=CC(N2CCNCC2)=C1C ZVVXHWDADZXWBK-UHFFFAOYSA-N 0.000 description 1
- GLNUVXISAQTTEO-UHFFFAOYSA-N n,n-diethyl-2-(2-methyl-3-piperazin-1-ylphenoxy)ethanamine;hydrochloride Chemical compound Cl.CCN(CC)CCOC1=CC=CC(N2CCNCC2)=C1C GLNUVXISAQTTEO-UHFFFAOYSA-N 0.000 description 1
- FUKWXUVCBRMHMG-UHFFFAOYSA-N n,n-diethyl-2-(3-piperazin-1-ylphenoxy)ethanamine;hydrochloride Chemical compound Cl.CCN(CC)CCOC1=CC=CC(N2CCNCC2)=C1 FUKWXUVCBRMHMG-UHFFFAOYSA-N 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- ILBIXZPOMJFOJP-UHFFFAOYSA-N n,n-dimethylprop-2-yn-1-amine Chemical compound CN(C)CC#C ILBIXZPOMJFOJP-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- RKJGMXLKNOGMHW-UHFFFAOYSA-N n-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-n',n'-dimethylethane-1,2-diamine;hydrochloride Chemical compound Cl.CN(C)CCNC1=CC(Cl)=CC(N2CCNCC2)=C1C RKJGMXLKNOGMHW-UHFFFAOYSA-N 0.000 description 1
- OQWONLSUJJURJK-UHFFFAOYSA-N n-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-n'-ethyl-n'-methylethane-1,2-diamine Chemical compound CCN(C)CCNC1=CC(Cl)=CC(N2CCNCC2)=C1C OQWONLSUJJURJK-UHFFFAOYSA-N 0.000 description 1
- YNGIHIMHWBYNMM-UHFFFAOYSA-N n-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-n'-methyl-n'-propan-2-ylethane-1,2-diamine Chemical compound CC(C)N(C)CCNC1=CC(Cl)=CC(N2CCNCC2)=C1C YNGIHIMHWBYNMM-UHFFFAOYSA-N 0.000 description 1
- TTWBJIUVOHVAKS-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-n',n'-dimethylethane-1,2-diamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C3=C(Br)NN=C3N=CN=2)=C1C TTWBJIUVOHVAKS-UHFFFAOYSA-N 0.000 description 1
- KBNOWZFLZPHXIY-UHFFFAOYSA-N n-[3-[4-(3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-n'-methyl-n'-propan-2-ylethane-1,2-diamine;hydrochloride Chemical compound Cl.CC(C)N(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(Br)=NNC=3N=CN=2)=C1C KBNOWZFLZPHXIY-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- ZYFWXHCSAMMYTM-UHFFFAOYSA-N n-[4-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2h-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NNC2=NC=NC(N3CCN(CC3)C=3C(=CC=C(Cl)C=3)C)=C12 ZYFWXHCSAMMYTM-UHFFFAOYSA-N 0.000 description 1
- IPGFGIIRPVVRGH-UHFFFAOYSA-N n-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenyl]-n',n'-diethylethane-1,2-diamine;hydrochloride Chemical compound Cl.CCN(CC)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C IPGFGIIRPVVRGH-UHFFFAOYSA-N 0.000 description 1
- OQTCXSMHKFCLSO-UHFFFAOYSA-N n-[5-chloro-2-methyl-3-[4-[3-(trifluoromethyl)-2h-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl]phenyl]-n',n'-dimethylethane-1,2-diamine;hydrochloride Chemical compound Cl.CN(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C=3C(=NNC=3N=CN=2)C(F)(F)F)=C1C OQTCXSMHKFCLSO-UHFFFAOYSA-N 0.000 description 1
- AOQFWLLHXULMFU-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n',n'-dimethylethane-1,2-diamine;hydrochloride Chemical compound Cl.C=12C(CC)=NNC2=NC=NC=1N(CC1)CCN1C1=CC(Cl)=CC(NCCN(C)C)=C1C AOQFWLLHXULMFU-UHFFFAOYSA-N 0.000 description 1
- MDUURHLHERLXHI-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n'-ethyl-n'-methylethane-1,2-diamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCN(C)CCNC1=CC(Cl)=CC(N2CCN(CC2)C=2C3=C(CC)NN=C3N=CN=2)=C1C MDUURHLHERLXHI-UHFFFAOYSA-N 0.000 description 1
- GMNMSTOAHVFJKE-UHFFFAOYSA-N n-[5-chloro-3-[4-(3-ethyl-2h-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-n'-methyl-n'-propan-2-ylethane-1,2-diamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=C(CC)NN=C2N=CN=C1N(CC1)CCN1C1=CC(Cl)=CC(NCCN(C)C(C)C)=C1C GMNMSTOAHVFJKE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 108010035114 procamine Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- IAHIMVFWYADCJJ-UHFFFAOYSA-N prop-1-enylcyclohexane Chemical group CC=CC1CCCCC1 IAHIMVFWYADCJJ-UHFFFAOYSA-N 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical group S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- ZXLIKOLOLSXZNT-UHFFFAOYSA-N tert-butyl-[3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-ynoxy]-dimethylsilane Chemical compound CC1=CC=C(Cl)C=C1N1CCN(C=2C=3C(C#CCO[Si](C)(C)C(C)(C)C)=NN(C=3N=CN=2)C2OCCCC2)CC1 ZXLIKOLOLSXZNT-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- XEFRYQPTIWSVGI-UHFFFAOYSA-N tributyl(2-methylbut-3-en-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C(C)C XEFRYQPTIWSVGI-UHFFFAOYSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56490804P | 2004-04-23 | 2004-04-23 | |
| US60/564,908 | 2004-04-23 | ||
| PCT/US2005/013860 WO2005117909A2 (en) | 2004-04-23 | 2005-04-22 | Kinase modulators and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007534687A JP2007534687A (ja) | 2007-11-29 |
| JP2007534687A5 JP2007534687A5 (https=) | 2008-07-24 |
| JP5213229B2 true JP5213229B2 (ja) | 2013-06-19 |
Family
ID=35463331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509678A Expired - Fee Related JP5213229B2 (ja) | 2004-04-23 | 2005-04-22 | キナーゼ調節因子および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8076338B2 (https=) |
| EP (1) | EP1750727A2 (https=) |
| JP (1) | JP5213229B2 (https=) |
| AU (1) | AU2005249380C1 (https=) |
| CA (1) | CA2563699C (https=) |
| WO (1) | WO2005117909A2 (https=) |
Families Citing this family (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| BRPI0418078A8 (pt) | 2003-12-23 | 2018-01-02 | Astex Therapeutics Ltd | composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto |
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CA2590961C (en) * | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US20090111805A1 (en) * | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| WO2006124865A2 (en) * | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
| WO2006130493A2 (en) | 2005-05-31 | 2006-12-07 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JP2009532475A (ja) | 2006-04-05 | 2009-09-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | ヤヌスキナーゼの阻害剤として有用なデアザプリン |
| GB0608176D0 (en) * | 2006-04-25 | 2006-06-07 | Astex Therapeutics Ltd | Pharmaceutical Compounds |
| EP2029592A1 (en) * | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2007125321A2 (en) * | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| EP2049500B1 (en) | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2008061108A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| AR064415A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| EP2137179B1 (en) * | 2007-03-15 | 2015-09-02 | Merck Sharp & Dohme Corp. | Pyridazinone derivatives useful as glucan synthase inhibitors |
| EA017389B1 (ru) | 2007-03-23 | 2012-12-28 | Амген Инк. | Гетероциклические соединения и их применение |
| UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| CN101918373B (zh) | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| NZ586346A (en) * | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US8193202B2 (en) | 2008-04-21 | 2012-06-05 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CA2743242A1 (en) * | 2008-11-11 | 2010-05-20 | Eli Lilly And Company | P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| US8334293B2 (en) | 2008-11-11 | 2012-12-18 | Eli Lilly And Company | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| HUE025547T2 (en) | 2008-12-19 | 2016-02-29 | Boehringer Ingelheim Int | Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD |
| WO2010078430A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| AU2010203512C1 (en) | 2009-01-08 | 2013-10-17 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| NZ595087A (en) | 2009-02-11 | 2013-03-28 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
| TW201100427A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted heterocyclic compounds |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
| CN102471338B (zh) | 2009-08-07 | 2014-07-02 | 默克专利有限公司 | 氮杂杂环化合物 |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| UA107938C2 (en) * | 2009-08-12 | 2015-03-10 | Syngenta Participations Ag | Heterocycles with microbicidal properties |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| PT2473049T (pt) * | 2009-09-04 | 2019-03-04 | Sunesis Pharmaceuticals Inc | Inibidores de tirosina quinase de bruton |
| MX2012004780A (es) | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
| ES2674275T3 (es) | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2569298B1 (en) * | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| EP2576542B1 (en) | 2010-05-25 | 2015-04-22 | Boehringer Ingelheim International GmbH | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| US9586961B2 (en) | 2010-07-09 | 2017-03-07 | Leo Pharma A/S | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| US9586938B2 (en) | 2010-07-29 | 2017-03-07 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| PT2643313T (pt) | 2010-11-24 | 2016-10-11 | Merck Patent Gmbh | Quinazolina carboxamida azetidinas |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| CA2825028A1 (en) * | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| DK3111938T3 (da) | 2011-04-01 | 2019-07-01 | Curis Inc | Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe |
| KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Akt 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| EP2694056B1 (en) | 2011-04-01 | 2019-10-16 | AstraZeneca AB | Therapeutic treatment |
| SG195085A1 (en) * | 2011-06-07 | 2013-12-30 | Pfizer | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| EP2548878A1 (en) * | 2011-07-21 | 2013-01-23 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| MX346095B (es) | 2011-09-12 | 2017-03-07 | Merck Patent Gmbh | Nuevas imidazol-aminas como moduladores de la actividad de cinasas. |
| CN103930407B (zh) | 2011-09-12 | 2019-02-26 | 默克专利有限公司 | 用作激酶活性调节剂的氨基嘧啶衍生物 |
| PH12014500943A1 (en) | 2011-11-30 | 2014-06-30 | Astrazeneca Ab | Combination treatment of cancer |
| SG11201402387WA (en) | 2011-12-22 | 2014-09-26 | Merck Patent Gmbh | Novel heterocyclic carboxamides as modulators of kinase activity |
| NZ631569A (en) | 2012-02-28 | 2016-10-28 | Piramal Entpr Ltd | Phenyl alkanoic acid derivatives as gpr agonists |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| WO2013182612A1 (en) | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| MX2015002887A (es) * | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
| CN113384546A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| AR093511A1 (es) | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas |
| CA2890288A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| SG10201800741QA (en) | 2012-11-29 | 2018-03-28 | Merck Patent Gmbh | BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| USRE48622E1 (en) | 2012-12-20 | 2021-07-06 | UCB Biopharma SRL | Therapeutically active pyrazolo-pyrimidine derivatives |
| SG11201504291SA (en) * | 2012-12-20 | 2015-07-30 | Ucb Biopharma Sprl | Therapeutically active pyrazolo-pyrimidine derivatives |
| JP2014156442A (ja) * | 2013-02-18 | 2014-08-28 | Nippon Rikagaku Kogyo Kk | アリールピペラジン誘導体又はその塩の製造方法 |
| CN104016985B (zh) * | 2013-03-01 | 2017-11-03 | 华东理工大学 | 一种吡唑并嘧啶化合物及其用途 |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| SG11201505999VA (en) | 2013-03-11 | 2015-08-28 | Merck Patent Gmbh | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
| WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| WO2014160521A1 (en) * | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| CN104072499A (zh) * | 2013-03-29 | 2014-10-01 | 黄传满 | 哌嗪取代嘧啶类化合物及其用途 |
| CN104119343A (zh) * | 2013-04-25 | 2014-10-29 | 苏州科捷生物医药有限公司 | 2-三氟甲基噻二唑类化合物及其用途 |
| JP5719985B2 (ja) * | 2013-08-01 | 2015-05-20 | 株式会社ポーラファルマ | ジフェニルメチルピペラジン誘導体 |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015078799A1 (en) * | 2013-11-27 | 2015-06-04 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN105899493B (zh) * | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物 |
| CA2944573C (en) | 2014-04-03 | 2022-10-25 | Merck Patent Gmbh | Combinations of cancer therapeutics |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| HRP20220522T1 (hr) | 2014-08-04 | 2022-06-10 | Nuevolution A/S | Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CN104292242B (zh) * | 2014-09-18 | 2017-05-17 | 广州必贝特医药技术有限公司 | 噻吩嘧啶类化合物和制剂及其制备方法和应用 |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| US10227347B2 (en) * | 2015-04-21 | 2019-03-12 | Guizhou Bailing Group Pharmaceutical Co., Ltd. | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof |
| GB201506933D0 (en) * | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN112625028B (zh) | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MX383744B (es) | 2015-07-02 | 2025-03-14 | Centrexion Therapeutics Corp | Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona. |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| AU2016311426B2 (en) * | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| CZ306987B6 (cs) * | 2015-10-26 | 2017-11-01 | Ústav experimentální botaniky AV ČR, v. v. i. | 2,6-disubstituované puriny pro použití jako léčiva a farmaceutické přípravky je obsahující |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| HUE055846T2 (hu) | 2016-05-20 | 2021-12-28 | Taiho Pharmaceutical Co Ltd | Új 5H-pirrolo[2,3-D]pirimidin-6(7H)-on származék |
| MX383856B (es) * | 2016-06-14 | 2025-03-14 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| JP7214632B2 (ja) | 2016-07-21 | 2023-01-30 | バイオジェン エムエー インク. | ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物 |
| TW201811795A (zh) | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基-吡咯并嘧啶酮化合物及其用途 |
| US20190343836A1 (en) | 2017-01-10 | 2019-11-14 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| CN108794480A (zh) * | 2017-04-28 | 2018-11-13 | 天津药物研究院有限公司 | 吡咯并嘧啶类化合物、其制备方法和用途 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| EA202091830A1 (ru) | 2018-01-30 | 2020-12-29 | Инсайт Корпорейшн | Способы и промежуточные соединения для получения ингибитора jak |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| US12286401B2 (en) * | 2018-07-31 | 2025-04-29 | The Trustees Of The University Of Pennsylvania | Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity |
| SG11202102343QA (en) | 2018-09-11 | 2021-04-29 | Curis Inc | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| US10829493B2 (en) | 2019-04-12 | 2020-11-10 | Blueprint Medicines Corporation | Compositions and methods for treating KIT- and PDGFRA-mediated diseases |
| WO2020210669A1 (en) | 2019-04-12 | 2020-10-15 | Blueprint Medicines Corporation | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2022101459A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| TW202421127A (zh) * | 2022-07-05 | 2024-06-01 | 日商大鵬藥品工業股份有限公司 | 5H-吡咯并〔2,3-d〕嘧啶-6(7H)-酮及其鹽體之結晶 |
| WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
| WO2024168104A2 (en) * | 2023-02-09 | 2024-08-15 | Caraway Therapeutics, Inc. | Modulators of trpml, their compositions and methods of use |
| WO2024168106A2 (en) * | 2023-02-09 | 2024-08-15 | Caraway Therapeutics, Inc. | Modulators of trpml, their compositions and methods of use |
| EP4687883A2 (en) * | 2023-04-05 | 2026-02-11 | Caraway Therapeutics, Inc. | Modulators of trpml, their compositions and methods of use |
| CN117586207A (zh) * | 2023-11-27 | 2024-02-23 | 浙江东亚药业股份有限公司 | 一种酮康唑侧链的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
| EP0514540B1 (en) | 1989-09-19 | 1996-07-17 | Teijin Limited | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6946449B2 (en) * | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| JP2005509612A (ja) | 2001-10-12 | 2005-04-14 | アイアールエム エルエルシー | 置換プリンの合成方法 |
| SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| EP1663962A4 (en) * | 2003-08-22 | 2007-08-22 | Dendreon Corp | COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION |
| KR100843526B1 (ko) * | 2004-02-27 | 2008-07-03 | 에프. 호프만-라 로슈 아게 | 피라졸의 접합 유도체 |
| GB0407723D0 (en) | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| CA2590961C (en) | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
-
2005
- 2005-04-22 WO PCT/US2005/013860 patent/WO2005117909A2/en not_active Ceased
- 2005-04-22 EP EP20050804792 patent/EP1750727A2/en not_active Withdrawn
- 2005-04-22 JP JP2007509678A patent/JP5213229B2/ja not_active Expired - Fee Related
- 2005-04-22 AU AU2005249380A patent/AU2005249380C1/en not_active Ceased
- 2005-04-22 US US11/568,173 patent/US8076338B2/en not_active Expired - Fee Related
- 2005-04-22 CA CA2563699A patent/CA2563699C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005249380C1 (en) | 2012-09-20 |
| EP1750727A2 (en) | 2007-02-14 |
| AU2005249380A1 (en) | 2005-12-15 |
| WO2005117909A3 (en) | 2006-04-27 |
| US20080076774A1 (en) | 2008-03-27 |
| AU2005249380B2 (en) | 2012-05-10 |
| CA2563699C (en) | 2014-03-25 |
| WO2005117909A2 (en) | 2005-12-15 |
| JP2007534687A (ja) | 2007-11-29 |
| CA2563699A1 (en) | 2005-12-15 |
| US8076338B2 (en) | 2011-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5213229B2 (ja) | キナーゼ調節因子および使用方法 | |
| AU2005322085B2 (en) | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases | |
| ES2935746T3 (es) | Inhibidores de desmetilasa-1 específica de lisina | |
| EP2044051B1 (en) | Pyridine and pyrazine derivatives as mnk kinase inhibitors | |
| AU2015225745B2 (en) | Heterocyclic compounds | |
| AU2009264431B2 (en) | Pyrazolo-quinazolines | |
| JP6276762B2 (ja) | キナーゼ阻害剤として活性な置換ピロール類 | |
| JP2023513854A (ja) | 大環状化合物およびその使用 | |
| JP6465996B2 (ja) | 3−アセチレニル−ピラゾール−ピリミジン誘導体、およびその製造方法およびその使用 | |
| RU2643361C2 (ru) | Новые производные триазолопиразина и их применение | |
| CN114401955A (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
| CN104837844A (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| EP4161657A1 (en) | Inhibitors of fibroblast growth factor receptor kinases | |
| PT1465921E (pt) | Espirocíclico-6, 7-di-idro-5h-pirazolo[1,2-a] pirazol-1-onas que controlam citocinas inflamatórias | |
| TWI797711B (zh) | 一種fgfr及其突變抑制劑,其製備方法和應用 | |
| BRPI0614502A2 (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto | |
| KR20240150419A (ko) | 아릴설폰아미드 화합물 | |
| KR102941832B1 (ko) | Cdk9 억제제 및 이의 용도 | |
| CA3184247C (en) | Fgfr and mutation inhibitor thereof, and preparation method therefor and use thereof | |
| WO2025231112A1 (en) | Sik2 modulators and uses thereof | |
| HK40065850A (zh) | 细胞周期蛋白依赖性激酶的抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080421 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080509 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110302 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110311 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110607 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110711 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110719 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110809 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110909 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120206 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120322 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20120412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120517 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120829 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120927 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121004 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121022 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130123 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130219 |
|
| RD17 | Notification of extinguishment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7437 Effective date: 20130221 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130225 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160308 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |